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"Education is a companion which no misfortune can depress, 
 no crime can destroy, no enemy can alienate, no despotism can enslave.  
At home, a friend, abroad, an introduction, in solitude a solace and in society an 
ornament.  
It chastens vice, it guides virtue, it gives at once grace and government to genius.  
Without it, what is man? A splendid slave, a reasoning savage." 
 
Joseph Addison (1672-1719) 
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1 Introduction   1 
1 Introduction 
1.1  Clinical relevance: bone defects 
Bone defects can be either inherited, occur following trauma, surgical correction of 
hereditary defects, through infection, congenital anomalies but can also arise due to 
operative intervention such as cyst and tumor resections (1). In general bone defects 
can be classified based on their morphological characteristics such as length, 
breadth and depth of injury. In addition to this the localisation of the defect plays an 
important role in the treatment of the defect. One differentiates between cortical, 
cancellous and cortico-cancellous defects with and without implication of the joint. 
For the treatment of osseous defects one has also to take into account the structure 
and biomechanical properties of the adjacent bones, and also the surrounding 
connective tissue such as muscle, tendon and skin in order to obtain a differential 
therapeutic diagnosis. Apart from this the local vascularisation plays a crucial role in 
the process of bone healing (2). 
 
1.2 Bone fracture healing 
Bone has the distinct feature to regenerate itself if the fracture is within a certain 
critical size. Bone fracture healing represents a unique physiological process to 
repair and restore bone function. In the human body bone healing resembles the 
stages of embryonic bone development. In the well orchestrated regenerative 
process of the bone four components at the injury site contribute to the healing at 
various extents; the cortex, the periosteum, the bone marrow, and the external soft 
tissues. The extent to which each of the compartments contributes to the process of 
regeneration depends on a number of factors at and around the injured site. The 
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factors can vary from cytokines, hormones, nutrient and oxygen supply, pH to 
mechanical stability of the fracture (3). Histologically, fracture repair can be 
differentiated into two different processes namely: primary (direct or cortical) and 
secondary (indirect or combined endochondral and intramembranous) healing. 
 
1.2.1 Primary fracture healing 
Primary fracture healing occurs only if the apposed fractured areas can be directly 
approximated. In real life this can be achieved if the anatomical space between the 
two ends is reduced and rigid fixation gives the required stability. The primary 
fracture healing takes place mainly through cortical involvement via the 
reestablishment of new Haversian systems by forming discrete remodelling units 
known as “cutting cones”. This is aimed to restore mechanical continuity (4). 
Mesenchymal stem cells and vascular endothelial cells produce osteoprogenitor cells 
that differentiate into osteoblast that eventually produce an osteon and subsequently 
a woven bone is formed. The latter is substituted by lamellar bone. In order to 
guarantee a successful primary fracture healing the distance between the fracture 
ends should be less than 2 mm and requires minimal interfragmentary strain (5-8). 
There is no callus formation in primary fracture healing. 
 
1.2.2 Secondary fracture healing 
Secondary fracture healing is the prevailing mode of repair in the majority of 
fractures, and it is characterized by a callus formation which emanates from relative 
stability and motion at the fracture site (3). As the name already denotes in the 
indirect fracture healing a cartilage is initially formed which later on in the process of 
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healing gets replaced by bone. Mesenchymal stem cells get recruited to the site of 
fracture where they proliferate and differentiate into cartilage which becomes calcified 
and eventually replaced by bone. Intramembranous periosteal bone formation leads 
to the formation of hard callus, whereas the endochondral ossification results in soft 
callus formation. Following a bone fracture, a haematoma is formed and an 
inflammatory response arises. This triggers an array of processes to take place, 
starting with angiogenesis followed by cartilage formation, cartilage calcification, 
cartilage removal and ending with bone formation and bone remodelling (9, 10).  
 
If the size of a bony defect is beyond a critical size the bone does not regenerate on 
itself. In such scenario the resultant defects present a major predicament for 
orthopaedic surgeons. In recent years the rise in bone defects has not only given a 
dilemma to the surgeons but represents now a substantial biomedical burden to the 
healthcare system (1). The demography of the population of the industrialized 
countries is shifting towards an older profile, making injury and disease of the skeletal 
system a more relevant clinical issue. It has been predicted that the percentage of 
persons over 50 years of age affected by bone diseases will double by 2020 (11). In 
case of large skeletal defects, the “gold standard” to treat such bony defects, is the 
use of autogenous bone grafts (12). 
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1.3 Bone grafting 
 
1.3.1 Principle 
The principle aim of bone repair is to promote and accelerate the bone healing, in 
order to obtain a bone that can withhold the mechanical load and provide stability to 
the skeleton. This is primarily achieved by means of a bone graft whose functions are 
to promote bone formation or osteogenesis and provide structural support. 
 
An ideal bone graft should possess the following properties: 
1.) Osteoinduction refers to a process whereby mesenchymal stem cells are 
recruited and prompted to differentiate into the osteogenic lineage, giving rise to 
osteoblasts (bone forming cells). A material is said to be osteoinductive if it has the 
property to induce bone formation at an ectopic site. One example of such a material 
is demineralised bone matrix (DBM). 
 
2.) Osteoconduction denotes a process where a bone graft acts as a platform on 
which cells required for bone formation can attach and proliferate. These materials 
offer an appropriate topology on which MSC can attach, spread, migrate and 
proliferate. 
 
3.) Osteogenity refers to generation of bone-forming cells. A graft or material is said 
to be osteogenic if it is capable of supplying and supporting bone forming cells (13, 
14). 
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1.3.2 Types of bone grafts 
The process of transplanting bone from one atomic site to another atomic site within 
the same individual is referred to as autogenous bone grafting. The sites where bone 
is usually harvested are proximal femur or tibia, femoral head, iliac crest and a 
resected rib. Autogenous bone graft remains until today the “gold standard” to treat 
bony defects as it possesses osteogenic properties (marrow-derived osteoblastic 
cells and preosteoblastic precursor cells), osteoinductive properties (non collagenous 
bone matrix and growth factors), and osteoconductive properties (bone mineral and 
collagen). Autogenous grafts are completely histocompatible, nullifying the fear of 
immune rejection and rendering immuno-suppression unnecessary. All these 
attributes make autogenous grafts the primary choice for graft materials for bone 
reconstructions (15). However, autogenous bone grafting is limited by restricted 
supply and donor site morbidity, including bleeding, hematoma, infection, muscle 
weakness, nerve injury and chronic pain (16, 17). 
 
The process of transplanting bone from one individual to another individual of the 
same species is referred to as allogenous bone grafting. Allografting is primarily done 
to support mechanical loads and resist failure at site where structural integrity is 
required (16). Allografts have grown over the years as evident through the rise in 
bone tissue banks across the world. The greatest disadvantage of using allografts is 
the possibility of transmitting viral diseases such as hepatitis B, hepatitis C and 
human immunodeficiency virus (HIV; 18). By thorough screening of the donors at the 
tissue banks one tries to reduce the risk of viral transmission. Besides this there are 
various methods now employed to sterilize bone grafts such as low dose irradiation, 
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physical debridement and ultrasonic washes to mention a few of the widely used 
techniques (19). Another main objective of sterilizing allografts is to obtain a more 
histocompatible bone by removing the antigen components of the graft that might 
elicit an immune response in the host and that still retains its biological and 
biomechanical properties. 
 
Although autogenous and allogenous bone grafts are a helpful tool in treating bony 
defects, due to their distinct disadvantages there is a need to look out for other 
conventional methods to treat bone defects in the future (16). In recent years a 
multitude of bionatural and synthetic bone graft substitutes have made their way to 
the market. Among the popular ones are calcium-phosphates, ceramics, 
demineralised bone matrix (DBM), and composite grafts (20, 21). The attractiveness 
of these bone graft substitutes is that they are devoid of surface antigens and hence 
do not mount an immunologic graft rejection, eliminate the risk of disease 
transmission as seen with allografts, and above all there is an infinite supply of the 
graft material. Bone graft substitutes though promising have their drawbacks like 
contour irregularities and structural failure, and mostly lack the osteoinductive 
property. 
 
The vast amount of techniques and materials available to the surgeon to treat bone 
defect reflects both the inadequate supply of individual bone and the necessity to find 
new tactics for reconstructive surgery of bone defects. Cell based tissue engineering 
might be an alternative solution for this dilemma and might overcome the numerous 
drawbacks as seen with the traditional graft material as mentioned above.  
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1.4 Tissue Engineering 
Tissue Engineering, an emerging field of the 21st century and one of the frontiers in 
biotechnology is an interdisciplinary field that involves the fusion of biomaterial 
science and life sciences (22). Tissue engineering has come a long way, and in order 
to make reasonable speculations on where this ever developing field is heading 
towards, it is important to understand where it had been. In the early years of tissue 
engineering around 1970 Green and colleagues at the children‟s hospital Boston, 
tried to generate new cartilage in vivo by seeding chondrocytes onto spicules of bone 
and thereafter implanting the cell-seeded 3D construct in nude mice. Though this 
experiment failed, he concluded that with the advancement of technology and the 
development of innovative biocompatible material it would be possible to generate 
new tissue in vivo (23). Most of the subsequent and important work in the field of 
tissue engineering was carried out around Boston, and it is considered that the 
modern roots of tissue engineering are deeply seated in Boston. Other eminent 
personalities who contributed to the field of tissue engineering at the early stages 
were Burke and Yannos who were able to produce a skin graft through the use of 
dermal fibroblast grown on collagen gels. One of the key moments in the history of 
modern tissue engineering was when Vacanti and Langer collaborated to design an 
appropriate scaffold for cell based tissue engineering (23). This new approach gave 
tissue engineering a whole new side as it attempted to seed cells on a synthetically 
created scaffold with known physical and chemical parameters, rather than in the 
older times where cells were seeded on naturally occurring materials. Scaffold 
development has from there onwards been an ever growing field, which gives tissue 
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engineering new perspectives and possibilities that would have been not achievable 
with biologically occurring materials.  
 
Cell based tissue engineering involves the construction of a three-dimensional 
scaffold that acts as a mechanical support on which the desired cells are grown 
followed by the implantation of the seeded scaffold to induce and direct the growth of 
new, healthy tissue (Fig.1; 24, 25). The Scaffold acts as a temporary matrix 
mimicking the structural and biomechanical properties of the extracellular matrix of 
the damaged tissue. In vitro cultured cells adhere and grow on the scaffold which will 
be then implanted on to the damaged site where it will favour the regeneration of new 
cells. As the cells grow in vivo they start generating their own extracellular matrix 
(ECM) and the scaffold starts to degenerate. In theory tissue engineering enables us 
to generate a scaffold of controlled size, shape, strength and composition that can be 
suited to replace an extracellular matrix of a tissue with specific biomechanical 
properties (26, 27).  
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Figure 1 Concept of cell based tissue engineering. Autologous stem cells are 
obtained via bone marrow aspiration. Mesenchymal stem cells are isolated via Ficoll 
gradient centrifugation and stem cell characteristics are determined. They are 
expanded in vitro to the desired cell number and thereafter put into the site of fracture 
either via injection or seeded on biocompatible scaffolds and implanted at the site of 
fracture where they will aid in regenerating new healthy tissue. (Adapted and 
modified from Pountos et al., 2006 (28)) 
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1.4.1 Bone Tissue Engineering 
 
1.4.1.1 Bone - Structure and Function 
Bone is a vascularised tissue that provides mechanical stability to the skeleton that is 
required for locomotion, load bearing and protection of the brain, spinal cord, heart 
and lungs. Furthermore it serves as a mineral reservoir for calcium and serves as an 
attachment ground for muscles, ligaments and tendons (29). It is composed of three 
different cell types, namely osteoblasts, osteocytes and osteoclasts that are confined 
in a highly organised extracellular matrix (ECM). 
 
 Osteoblasts are derived from mesenchymal stem cells and their primary function is 
to synthesize the major protein content of the ECM. In addition to this they induce 
and downregulate osteoclasts and express genes required for calcification. 
Osteoblasts are large polyhedron shaped cells of 20-30 µm in size. Typical markers 
for osteoblast differentiation are type I collagen (COL I), alkaline phosphatase (ALP), 
runt related protein 2 (RUNX 2) and osterix (OSX) for early stage and osteocalcin 
(OCN), osteopontin (OPN), osteonectin (ON) and bone sialoprotein (BSP) for the late 
stage of osteoblastic differentiation (30). Osteoblasts once trapped in the ECM 
mature into osteocytes that are the most numerous and longest-lived cells in bone. 
Osteocytes are stellate and found in the interior of bone inside lacunae, whereas 
osteoblast and osteoclast are situated on the bone surface. They are assumed to 
sense bone deformation and send out signals for requirement of adequate bone 
modelling (31, 32). Osteoclasts are derived from monocytes and their primary 
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functions are bone resorption and bone turnover. The balanced interplay between 
bone formation through osteoblasts and bone resorption through osteoclasts is 
important to maintain bone strength in adulthood. The osteoblast and osteoclast 
communicate with each other through transmembrane proteins or integrins, that 
either link cells or the cells to the extracellular matrix and through secreted signalling 
proteins such as RANK-ligand which regulate osteoclastic activity. 
 
 The ECM consists of an organic and an inorganic phase. The organic part also 
known as the osteoid material is fundamentally formed from collagen type I. Apart 
from this other constituents of the organic part are proteoglycans, glycoproteins, 
proteins from plasma, growth factors and proteins with g-carboxyglutamic acid. The 
inorganic part is formed through hydroxyapatite crystals which consist of 
calciumphosphate and in smaller quantities by magnesium, sodium, potassium, 
manganese and fluoride (33).  
 
In adults one can distinguish between two types of bone depending on the 
architecture of the tissue within the bone. In Cancellous bone, the tissue is arranged 
in a trabecular pattern and in cortical bone the bone tissue is arranged in a compact 
pattern. Cancellous bone is more porous and flexible compared to cortical bone and 
are present in the metaphysis of long bones, iliac crest and the vertebral bodies. 
Cortical bone is ubiquitously present in long, short and flat bones (17). 
 
1.4.2 Scaffolds for bone tissue engineering 
Biomaterials as scaffolds for bone tissue engineering serve certain biological 
functions by substituting or repairing different bone in the skeleton or by even guiding 
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bone repair. Over the past 60 years the field of material science revolving around 
scaffold development has grown tremendously. One can distinguish between three 
different generations of biomaterials: First generation biomaterials were developed 
during 1960s and 1970s and their main function was to resemble the physical 
properties of the bone to be replaced and to cause minimal toxic effect to the host 
(34). Examples include commercially pure Ti (CP Ti®) and Ti6Al4V (ASTM F136®) the 
most commonly used titanium alloys in orthopaedics (11). With the design of the 
second generation biomaterials one tried to produce a more sophisticated scaffold by 
moving from an inert biomaterial to a more bioactive and biodegradable material. 
One of the first second generation biomaterial was bioactive glass followed by 
synthetic hydroxyapatite (HA) ceramics which were routinely used in the mid 1980s 
as powder, porous implant and coatings on metallic prostheses to provide bioactive 
fixation (35). Finally the third generation of biomaterials appeared which tried to 
stimulate specific cellular responses at the molecular level (35). For these 
biomaterials the attributes of bioactivity and biodegradability are combined. A popular 
example of this group is demineralised bone matrix (DBM), which is widely used in 
clinical applications as an alternative to autografts for filling bone defects (36). 
 
Scaffolds play a very important role in cell based tissue engineering, they act as 
temporary matrices on which desired cells can attach, spread, proliferate and 
eventually differentiate into a specific lineage. The scaffold should ideally be 
designed in a way that it matches the geometry and size of the defect. Besides its 
external appearance it should facilitate the ingrowth of capillaries and vessels 
(angiogenesis) so that cells residing in the interior of the scaffolds are sufficiently 
supplied with oxygen and nutrient. This is warranted by micro - and macroporosity of 
the scaffold. A pore size of approximately 10 µm is required for capillary ingrowth and 
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cell-matrix interaction whereas a pore size of 150-900 µm allows for nutrient supply 
and waste removal (37-40). 
 
One can group scaffolds into organic and inorganic matrices. Organic scaffolds 
include natural graft materials and biodegradable polymers, either synthetic or 
naturally occurring ones. Within the natural biodegradable polymers one can find 
among others collagen, fibrinogen, chitosan, hyaluronic acid and starch. These 
naturally occurring polymers have distinct advantages like low immunogenic 
potential. Synthetic biodegradable polymers are more widely used in the biomedical 
engineering field. Well known examples are for instance poly (-caprolactone), poly 
(propylene fumarate), and poly (-hydroxyacids). Polylactic acid (PLA) and 
polyglycolic acid (PGA) belong to the family of poly (-hydroxyacids) and are widely 
used in the production of 3D scaffolds. They have been also approved by the Food 
and Drug administration to be used as bone fixation devices such as pins and screws 
(ReFIX Xtremi-T®, LLC®) and PDS/PGA staple (Mitek®), to name a few. Their 
application is restricted to fractures with low mechanical modulus (20). The key 
advantages of using biodegradable materials over inorganic substance in bone repair 
are: (i) a second surgery is not required to remove the implant, as it will degrade on 
its own over the period of regeneration and the degradation products are excreted 
from the body through natural pathways, (ii) the progressive loss of implant material 
results in the induction of bone formation by osteoblasts (41). Inorganic scaffolds 
include calciumphosphate-based ceramic or cement and calciumsulphate-based 
scaffolds and bioactive glasses (42). Calciumphosphate-based ceramics are 
currently employed by orthopaedic surgeons in reconstructive surgery. Several 
studies have shown that good results could be obtained with ceramic implants used 
for bone defects (43, 44). Most notably calciumphosphate-based ceramics have been 
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used as bone substitutes either in bulk form or as granules and in combination with 
cells from the bone marrow. The benefit of using ceramic based implant lies in their 
distinct properties of being biocompatible, bioactive and osteoinductive. However due 
to their low tensile strength and brittle nature they can not be employed at sites of 
significant torsion, bending, or shear stress (11, 38, 45).  
 
Ideally scaffolds should have the following properties to be used in cell based tissue 
engineering applications: First and foremost the scaffold should be biocompatible. It 
should not mount an immune response within the host nor should it be cytotoxic. In 
addition the scaffold should possess adequate mechanical strength to sustain 
handling and during the patients normal activities. The scaffolds must be sterilizable 
to prevent any sort of infection or transmission of viral diseases. Furthermore the 
porosity of the scaffold is important. The scaffold requires an interconnected porous 
architecture that supports vascularisation and exchange of nutrient and oxygen. In 
addition scaffolds must be biodegradable and the byproducts generated during 
degradation should be non toxic to the host and easily removable by the body‟s own 
metabolic processes. The scaffold should optimally resorb at the same rate as the 
tissue is repaired (46, 47). Another desirable property would be the molding of the 
scaffold to match the size and geometry of the defect and as well a radioopaque 
nature in order to discriminate between bone and implant via radiography (45, 48). 
Scaffolds derived from native osseous tissue, are preferentially used in bone tissue 
engineering because of their close resemblance in structure and function to 
autologous bone (49). Nowadays bone tissue engineering is focusing more on 
scaffolds that are biological in nature and are able to carry cells and provide an 
environment for them to proliferate and differentiate towards the osteogenic lineage. 
One such type of scaffold is the demineralised bone matrix (DBM). 
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Demineralised bone matrix (DBM) is a third generation biomaterial and has been 
already successfully used in clinical applications, mostly to fill in bone defects (11). 
Unlike synthetic materials, DBM is known to be osteoinductive and stimulate bone 
formation both in heterotopic and orthotopic implant sites. In 1965, Marshall Urist 
discovered the osteoinductive properties of DBM scaffolds. She was able to see 
bone formation when DBM scaffolds were placed ectopically in subcutaneous tissue 
(50). Their osteoinductive nature is attributed to residual matrix incorporated 
osteogenic factors such as bone morphogenetic proteins (BMPs) and other non 
collagenous proteins retained within these scaffolds (15). It has been shown that 
BMSC grown on DBM have an increased potential to differentiate into the osteogenic 
lineage. 
 
1.4.3 Stem cells 
Stem cells are found in almost all multicellular organisms and are characterized by 
their self-renewal potential and their ability to differentiate into a wide variety of cells. 
They can be differentiated into embryonic stem cells and adult stem cells. 
 
1.4.3.1 Embryonic stem cells 
Embryonic stem cells (ES) are touted for their pluripotency and are harvested from 
the inner cell mass of blastocyst during gastrulation, an early stage during embryonic 
development. ES have the unique ability to give rise to all tissues derived from the 3 
embryonic germ layers namely: ectoderm, endoderm, and mesoderm. They have 
been shown to differentiate into the osteogenic lineage both in vitro and in vivo (51-
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53). The pluripotency of ES is governed by a set of transcription factors, namely OCT 
4 (Pou5f1), SOX2 and NANOG (54-57). Even though their pluripotent nature makes 
them an ideal candidate for tissue engineering applications, however their 
predisposition for teratoma formation and their isolation from embryos makes them a 
distant cell source (1). Therefore, research has made a significant effort to identify a 
postnatal cell source that is multipotent. 
 
1.4.3.2 Human mesenchymal stem cells 
Human mesenchymal stem cells (hMSC) are widely used in tissue engineering 
applications because of their multipotentiality, relative ease of isolation and their high 
proliferation profile. They were first described by Friedenstein and colleagues in 1970 
as colony-forming unit-fibroblast (CFU-F; 58). Their ability to differentiate into the 3 
classic lineages, that is to say chondrogenic, adipogenic and osteogenic were first 
shown by Pittenger et al. in 1999 (Fig. 2; 59, 60). Primarily MSC are obtained from 
the bone marrow but can also be derived from adipose tissue, umbilical cord, 
amniotic fluid, skeletal muscle and, in low numbers from peripheral blood (61). 
 
 Over the years our understanding over these unique cells has taken great strides 
forward, but nevertheless we still have not identified a specific marker that could 
distinguish this subset of cells from the remainder. Currently we are following a series 
of criteria set by the International Society for Cellular Therapy (ISCT) that defines 
MSC. According to these criteria MSC must be plastic-adherent, >95% of the MSC 
population must express the surface antigens CD105, CD73 and CD90 and must 
lack the expression of CD45, CD34 and CD14. MSC must also be able to 
differentiate in vitro into the osteogenic, adipogenic and chondrogenic lineage and 
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this must be demonstrated via staining (62, 63). The search for a specific marker 
remains a hot topic in the present time. 
 
 BMSC isolated both from animals and humans have been already administered in 
combination with 3D construct to sites of muscoskeletal defects in experimental 
animals to regenerate bone. Bruder et al. for instance delivered hMSC loaded on 
ceramic into critical sized defects in the femur of adult athymic mice. Their study 
showed that the ceramic carrier with cells resulted in a better bone formation than 
ceramic carrier without cells after 12 weeks of implantation (64). Another group 
reported successful regeneration of large bone defects in humans through the 
implantation of autologous hMSC seeded on macroporous hydroxyapatite scaffolds 
(44). This group also followed up this study (post surgery) and checked for durability 
of the regenerated bone after 6 to 7 years. They have observed a good integrity of 
the implants was maintained even after 7 years (65). In contrast several other groups 
failed in regenerating large bony defects indicating that the optimal combination of 
scaffold material, design and cells has yet to be found (66).  
 
1.4.3.2.1 The stem cell niche 
The concept of stem cell niche was first introduced by Schofield in 1978 (67). He 
suggested that haematopoietic stem cells (HSC) could proliferate infinitely without 
losing their stem cell characteristic when they reside at a particular area he coined 
stem cell niche. Cipolleschi described that the stem cell niche is an area of extreme 
low oxygen (68, 69). Therefore mesenchymal stem cells that are derived from the 
bone marrow are assumed to reside in an hypoxic microenvironment (70). They 
coexist with HSC (71). It is believed that immature progenitors are located in areas of 
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low oxygen whereas more committed progenitors exhibit places with more oxygen in 
either closer to blood vessels.  
 
 
Figure 2 Characteristics of MSC. MSC are able to self renew themselves and give 
rise to colony forming unit-fibroblasts (CFU-F). Each of this unit is able to differentiate 
into a variety of lineages depending on the stimulus given. Here we show their 
classical differentiation ability towards bone, cartilage and fat respectively. (Adapted 
and modified from Otto et al., 2004 (72)) 
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1.4.3.3 Immortalised hMSC (SCP-1) 
Though hMSC have their advantages of being a suitable candidate for bone tissue 
engineering applications, only 0.001-0.1% of nucleated cells derived from the bone 
marrow are MSC. These low numbers necessitates the need of culture expansion in 
vitro before clinical use. Cell based tissue engineering requires a high number of 
cells, MSC tend to reach replicative senescence before they can grow to the required 
cell number (73). It has been reported that hMSC will loose their proliferation 
potential, homing and differentiation potential once they reach a maximum of 20-40 
population doublings in vitro (9, 74, 75). Numerous studies have revealed that 
telomere shortening plays a crucial role in the life span of somatic cells in culture 
including MSC (76, 77). During cell division the telomere length shortens and results 
in senescence and growth arrest. Telomere length can be maintained despite cell 
division through a ribonuclear protein complex telomerase which serves as a 
telomeric template and a subunit that has a reverse transcriptase activity. Human 
MSC are known to lack telomerase activity in vitro (78, 79). Therefore numerous 
groups immortalised hMSC through the incorporation of the human telomerase 
reverse transcriptase (hTERT) transgene under the control of a constitutive promoter 
that would prevent hMSC to enter senescence-associated growth arrest. They were 
also able to show that even after immortalisation the hMSC retained their ability to 
differentiate into several lineages (80-83). Nakahara and colleagues could show that 
immortalised hMSC were able to form bone in mice (84). 
 
Our Lab has created an immortalised hMSC line through the ectopic expression of 
hTERT using lentiviral gene transfer, that we call SCP-1 (Single cell picked-clone 1). 
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We were able to show that even after long term culture (2 years) the cells did not 
show any malignant transformations (85). 
 
1.5 Hypoxia in tissue engineering and regenerative medicine 
Though tissue engineering has been in existence for decades it‟s still a mere vision 
of putting the concept of tissue engineering into reality. One of the major drawbacks 
in tissue engineering is the occurrence of a reduced oxygen tension within the 
interiors of a scaffold. The lack of vessel formation within a scaffold during the initial 
stages of implantation leads to an inadequate supply of oxygen, nutrients and a 
hindered waste removal that additively leads to the death of cells. Apart from the 
death of cells it also brings about the uneven distribution of cells within the scaffold 
that might result in a poor quality of the resulting tissue (86). In living organisms the 
distance between cells and capillaries, that on one hand supplies nutrient and 
oxygen to the cells and on the other hand helps in the removal of metabolic waste 
products, lies between 20 and 200 µm (87). Therefore cells residing within the core of 
large 3D constructs will face suboptimal oxygen supply (17). 
 
Likewise, at the site of fractured bone, a milieu of reduced oxygen triggers bone 
healing further linking hypoxia to osteogenic differentiation of bone precursor cells 
(88). It is thus evident that cells that are utilized to regenerate bone tissue will face 
hypoxic conditions, either when used in the setting of bone tissue engineering or 
whenever a fracture has occurred (86, 89, 90).  
 
When exposed to hypoxia, cells respond via a complex signalling cascade, in which 
the hypoxia-inducible factor 1 (HIF-1 plays a predominant role (91-94). HIF-1 
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leads to an upregulation of genes, which orchestrate cell metabolism and survival 
under low oxygen conditions, including anaerobic glycolysis, formation of new blood 
vessels, or ultimately induce apoptosis (91-95). 
 
1.5.1 HIF-1 
HIF-1 is a transcription factor that belongs to the basic helix-loop-helix-Per-ARNT-
SIM (bHLH-PAS) protein family. It is required for attaining homeostasis under 
reduced oxygen tension and was discovered in 1992 (96). HIF-1 is stably 
expressed under reduced oxygen tension. It heterodimerises with HIF-1which is 
constitutively expressed and is independent of oxygen concentration (97). Once the 
heterodimer is formed there is a configurational change taking place within the dimer 
allowing it to bind to the hypoxia responsive element (HRE), a DNA sequence 
residing on the target gene. This in turn will trigger the activation of transcription of 
genes involved in various biological processes that are vital for sustaining 
homeostasis in hypoxic milieu, such as erythropoiesis and glycolysis, which instantly 
counteracts oxygen deprivation. Angiogenesis, in either sprouting of vessels from 
pre-existing vessels is prompted through the expression of vascular endothelial 
growth factor (VEGF), which is a long term adaptation to low oxygen tension (Fig. 3). 
 
Hif-1 gets degraded through its oxygen dependent degradation domain (ODDD) via 
the E3 ubiquitination pathway. In order for Hif-1 to be degraded, proline residues 
situated at the ODDD need to be hydroxylated by prolyl hydroxylase domain-
containing proteins (PHD). Following the hydroxylation the von Hippel-Lindau tumor 
suppressor protein (pVhL) is able to bind to the site orchestrating a cascade of 
reaction to take place winding up in the proteosomal degradation of the Hif-1 via the 
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E3 ligase complex (91, 98). The proteosomal degradation of Hif-1 can be inhibited 
through substances such as desferrioxamine (DFO) that renders PHD inactive. PHD 
requires besides molecular oxygen, iron as a co-factor to hydroxylate the proline 
residues. DFO being an iron chelator takes away the iron from PHD and hence 
making it inactive, and therefore Hif-1 degradation is inhibited even under normoxia 
(Fig. 3; 99). The transcription product of both HIF-1 and HIF-1 are ubiquitously 
expressed and is independent of oxygen concentration. 
 
 
Figure 3 Regulation of HIF-1 by oxygen concentration. During low oxygen 
tension HIF-1 is stable and gets translocated into the nucleus where it will bind to 
HIF-1. The hetero dimerization brings about a configurational change within the 
protein complex allowing it to bind to a specific DNA sequence on the target gene 
and thereby initiating the transcription of various genes that mediate hypoxia 
response mechanisms. Under high oxygen tension Hif-1 gets hydroxylated at its 
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oxygen dependent degradation domain (ODDD) and C terminal transactivation 
domain (CTAD) via PHD and FIH enzymes respectively. Hydroxylation enables the 
von-hippel-lindau tumor suppressor protein (VhL) to bind to Hif-1 triggering its 
ubiquitylation and destruction. (Adapted and modified from Maxwell, P.H., 2008 
(100)) 
 
1.5.2 Hypoxia and its role in osteogenic differentiation 
Lately, it was shown that differentiation processes are also affected by hypoxia (101-
107). Malladi and colleagues for instance reported that osteogenic differentiation was 
reduced when cells were differentiated under 2% oxygen (104). Several articles have 
since provided proof that osteogenic differentiation may be negatively affected by 
hypoxia (104, 106-111). It was shown that hypoxia brings about a decrease in the 
expression level of key transcription factors and osteogenic marker genes, such as 
RUNX 2, OCN, and COL 1 (106, 107, 109, 111).  
 
Although it remains to be determined what true hypoxic conditions are, it is now 
widely accepted that 21% of oxygen as commonly used in cell culture is rather a 
state of artificial hyperoxia (103, 112, 113). In consequence, low oxygen tensions are 
considered to be a more physiological milieu for stem cells (103, 112, 114-116). In 
accordance with these considerations, a recent study provided evidence that 
preconditioning hMSC in low oxygen improves their therapeutic potential (117). It 
was shown that hypoxic preconditioning improved the homing and tissue-repairing 
capacity of hMSC, and besides this, cells preconditioned in hypoxia displayed an 
increased motility. Another study documented that MSC would survive longer after an 
assault of deadly hypoxia if preconditioned in low oxygen (118). In addition, it was 
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proposed that activation of the HIF-1 pathway accelerates bone regeneration in 
vivo, suggesting that hypoxia is an important co-factor in bone healing (119). 
 
Wan and colleagues conducted experiments in osteoblasts of mice that lacked pVHL 
and therefore had a constitutive HIF-1 activation and observed that these mice had 
an increased vascularity and produced more bone in response to distraction 
osteogenisis compared to mice that lacked HIF-1 which had an impaired 
angiogenesis and bone healing (119). Similarly Wang et al. showed that mice 
overexpressing HIF-1 in osteoblasts through the deletion of the von Hippel-Lindau 
gene (VHL) expressed high levels of vascular endothelial growth factor (VEGF) and 
developed extremely dense, heavily vascularised long bones. In contrast they 
observed in mice lacking HIF-1 in osteoblasts an opposite skeletal phenotype; in 
either the long bones were substantially thinner and less vascularised. In mice that 
lacked both VHL and HIF-1 the phenotype of the long bone was intermediate 
between the mice lacking HIF-1 through the deletion of VHL and the mice 
overexpressing HIF-1(94). Interestingly Wang et al. were able to show that upon 
HIF-1 knockdown the mice produced an elevated level of HIF-2 and as both HIF-
1 and HIF-2 have overlapping function, HIF-2 might substitute partially for the 
loss of function of HIF-1. This compensatory mechanism might also explain why 
HIF-1 knockdown mice were still able to develop functional bone (94). Taken 
together the results of Wang and Wan depicts HIF-1 pathway as a critical mediator 
of neoangiogenesis that is required for bone development and regeneration. Their 
studies collectively imply a possible therapeutic application of HIF-1 activators to 
improve bone repair. 
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1.6 Aim of this study 
As hMSC used in tissue engineering are subjected to low oxygen concentrations, it is 
of critical importance to investigate how cells respond to hypoxia and how their 
regenerative and differentiation potential can be maintained despite exposure to 
hypoxia (120).  
 
In this study we therefore first asked whether constant exposure of cells to low 
oxygen (2%) affects proliferation of hMSC. We then assessed whether the constant 
exposure to 2% O2 would inhibit osteogenic differentiation of hMSC. We then 
analysed whether preconditioning hMSC in hypoxia would restore the differentiation 
potential. To address this question, we have investigated two different setups of 
differentiation; one, where cells were grown in 2% oxygen prior to osteogenic 
differentiation under 2% O2. Despite the claim that low oxygen may be more 
representative of physiological conditions, this setup will be referred to as hypoxic 
preconditioning for consistency with conventional terminology. In the second case, 
cells were expanded under a so-called normoxic environment (21% O2). Thereafter, 
they were osteogenically induced under 2% O2. 
 
We then addressed the question why osteogenic differentiation is delayed under 
hypoxia. In order to answer this question we have performed a clonogenic assay and 
semi quantitative RT-PCR for embryonic stem cell markers. We further asked what 
the role of HIF-1 is during hypoxic preconditioning with respect to the osteogenic 
differentiation potential of hMSC. To solve this question we transiently knocked down 
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HIF-1 using silencing RNA in hypoxia or stabilised Hif-1 using DFO treatment in 
normoxia. 
 
As a next step, we wanted to see whether SCP-1 can be used as a model system for 
hMSC. For that we first characterised SCP-1 with respect to their growth kinetics, 
DNA synthesis, clonogenic potential and their stem cell characteristics in both 
normoxia and hypoxia. SCP-1 were then differentiated into the osteogenic and 
adipogenic lineages using the hypoxic preconditioned and normoxia setup. Finally we 
screened for the potential of hypoxia preconditioned SCP-1 to survive and proliferate 
on DBM scaffolds and their oxygen consumption in 2D versus 3D.  
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2 Materials and Methods 
2.1 Cell culture 
 Table 1 Characteristics of hMSC donors 
Donor 
hMSC lot 
number 
Age Sex Race 
XI 1F2155 24 male Other* 
XIII 4F0591 32 male caucasian 
XIV 4F0760 25 female caucasian 
XV 6F3837 34 female caucasian 
 *Other refers to mixed ethical background 
Human mesenchymal stem cells were purchased from Lonza (Verviers, Belgium) at 
passage 2 (P2). The cells were expanded in minimum essential medium alpha with 
L-glutamine (MEM; Invitrogen, Carlsbad, California) supplemented with 10% fetal 
bovine serum (FBS; Sigma, Munich, Germany) and 40 IU/ml penicillin/streptomycin 
(PAA Laboratories GmbH, Pasching, Austria) at 37˚C in a 5% carbon dioxide 
environment in a standard cell culture incubator (21% O2). Cell stocks were frozen at 
P5 in a -80˚C freezer. Cells were not grown beyond 60% confluency during 
expansion culture. Table 1 reflects the various donors used in this project. Donor XV 
was the central donor for the studies. 
 
SCP-1 was derived from donor XIV through a lentiviral transduction of the transgene 
hTERT. This cell line was derived from a single cell-picked clone of hTERT-
immortalized hMSC and was therefore named „„single cell picked-clone 1‟‟ (SCP-1). 
These cells were shown to differentiate toward the adipogenic, chondrogenic, and 
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osteoblastic lineage like their non immortalized counterparts (85). One important 
feature of SCP-1 is that they proliferate faster than primary hMSC. We have selected 
passage 72 for SCP-1 as early passages tended to be in their lag phase. Passages 
around 70 were in their exponential phase of growth and were also shown to 
differentiate into the 3 lineages (osteogenic, adipogenic and chondrogenic). In 
addition to this it was shown that SCP-1 do not produce any neoplastic 
transformations, when implanted subcutaneously into immuno-deficient athymic nude 
rats (85). 
 
2.2 3D culture 
Static three-dimensional (3D) culture was performed as described previously (86). In 
brief, cylindrical bovine demineralised bone matrix (DBM; Tutogen, Neunkirchen, 
Germany) scaffolds of 9mm in diameter and 5mm of height (Fig. 4) were seeded with 
1 million hMSC/SCP-1 cells according to a standardized protocol (121). The scaffold 
was initially centrifuged in complete medium at 500 x g for 5 minutes to remove air 
that was trapped within the scaffold and to get rid of any chemical residues that were 
left on the scaffold from the demineralisation step. Initial centrifugation of the scaffold 
with medium resulted in discolouration of medium from light red to yellow. The 
centrifugation step of scaffold with alpha MEM was repeated as often as required 
until the medium retained its colour indicating that the pH remained constant. The 
DBMs were then placed into 48 well plates. Thereafter 500 µl of cell suspension 
containing 1 million cells were pipetted onto the scaffold. Every 20 minutes, during 
the first 2 hours, the 3D construct was turned over and cell suspension was reseeded 
on top of the scaffold. In this way it was made sure that the majority of the cells 
adhered to the scaffold rather than to the plastic surface of the 48 well. With this 
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seeding technique a seeding efficiency of 90% was achieved. The cell-scaffold 
constructs were then transferred to a 24-well-dish (Nunc, Wiesbaden, Germany) and 
cultured under standard conditions. 
 
 
Figure 4 DBM Scaffold (A) Bird view of scaffold. (B) Side view of scaffold. 
 
2.3 Hypoxia 
To study the effect of hypoxia on human mesenchymal stem cells, hMSC were kept 
in a multi-gas incubator (MCO-5M, Sanyo, Pfaffenhofen, Germany) that maintained a 
gas mixture composed of 93% N2, 5% CO2 and 2% O2.  The oxygen concentration 
was maintained at 2% by the delivery of nitrogen. If O2 percentage rose above the 
desired level, N2 gas was automatically injected into the system to displace the 
excess oxygen. We have used 2% oxygen for our experiments as hMSC in 3D 
culture are exposed to as little as 2% of oxygen in vitro. However, we are well aware 
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that 2% oxygen may be more physiologic for certain cell types than the so-called 
normoxia (21%). Despite the claim that low oxygen may be more representative of 
physiological conditions, 2% of oxygen will be referred to as hypoxia for consistency 
with conventional terminology.  
 
2.4 Passaging of cells 
Cells were passaged at around 60% confluency into fresh culture flasks. Initially the 
spent medium was aspirated off and cells were washed with PBS in order to remove 
the last bit of medium remains. Thereafter cells were trypsinised with 1x trypsin for 
approximately 5 minutes at 37˚C. Trypsin is a serine proteinase that detaches the 
cells from the surface of flask by cleaving the proteins that bind the cells to the plastic 
surface. Trypsin was neutralised by adding double the amount of fresh medium into 
the flasks. Cells were resuspended thoroughly in order to get single cells and then 
were counted using a Neubauer chamber. The cell suspension was transferred into a 
suitable falcon tube and centrifuged at 500 x g for 5 minutes. The supernatant was 
aspirated off and the pellet was resuspended in fresh medium, to get rid off the 
trypsin. Finally the cells were plated at a density of 2500 to 6500 cells/cm2 into a 
sterile culture flask, so that on the next day the confluency of the cells was around 
20% to 50% respectively. 
 
2.5 Cell counting using Neubauer cell chamber 
Cells were counted using the Neubauer cell chamber. Following trypsinisation and 
resuspension 10 µl was pipetted on either one of the chambers of the neubauer cell 
chamber. Afterwards the 4 external quadrants (A, B, C, D) were counted and thereby 
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care was taken not to count cells that either lied on the right and top margins of each 
quadrant. The final cell count was determined using the following formula: 
[(A+B+C+D)/4] x 104 = total cell number/ml 
 
2.6 Cryopreservation and thawing of cells 
Cells were trypsinised and counted as above and around 0.5 x 106 cells were frozen 
using freezing medium in a cryovial. The freezing medium consisted of 70% culture 
medium, 20% FBS and 10% dimethyl sulfoxide (DMSO). DMSO is an important 
constituent of cryoprotectant vitrification mixture, which prevents ice crystal 
formation, and thereby protects cells from shear strain. Cryovials were stored for 
around 15 minutes in dry ice until cell suspension within cryovials solidified and then 
transferred either to -80˚C or into liquid nitrogen tank for prolonged preservation. 
 
In order to thaw cells, vials from nitrogen tank or -80˚C were thawed in a 37˚C water 
bath until the cell suspension became liquid. Following this the suspension was 
transferred into a 15ml falcon tube, containing 2 ml of fresh medium and centrifuged 
at 500 x g for 5 minutes. The supernatant was aspirated off and the pellet was 
resuspended with fresh warm culture medium and finally transferred into culture 
flask. After 24 hours of incubation medium was changed, in order to remove the non 
adherent cells, which have succumbed during the process of cryopreserving and 
thawing. 
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2.7 Induction of osteogenic differentiation 
For osteogenic differentiation, P5 vials were thawed and cultured as described 
above. After trypsinization, P6 hMSC were plated in a 6 well plate (NUNC, 
Wiesbaden, Germany) at a density of 3000 cells/cm2 (122). They were cultured under 
normoxia until subconfluency (70-80 %) was reached. Subconfluency was usually 
attained 3 days after plating. Following subconfluency, 3 out of the 6 wells in each 
plate were induced to differentiate by adding osteogenic differentiation medium as 
described previously (121). The differentiation medium consisted of DMEM high 
glucose medium (PAA Laboratories GmbH, Pasching, Austria) supplemented with 
10% FBS, 40 IU/ml penicillin/streptomycin, 100 nM dexamethasone (Sigma, Munich, 
Germany), 10 mM β-glycerophosphate (Sigma, Munich, Germany ) and 50µM L-
ascorbic acid 2-phosphate (Sigma, Munich, Germany). As a negative control, the 
remaining 3 wells were cultured further with complete medium. After induction, the 
plates were either incubated in a low oxygen atmosphere of 2% O2 for the remaining 
period of differentiation (hypoxic samples; Fig. 5B) or they were kept under normoxic 
conditions (normoxic control samples; Fig 5A). Every 3 days, a medium change was 
carried out.  
 
2.8 Hypoxic preconditioning 
Hypoxic preconditioning was established by expanding P6 hMSC under hypoxic 
conditions (2% O2) until subconfluency was reached. Osteogenic differentiation was 
then carried out under hypoxia (2% O2) in the same way as described for the hypoxic 
samples (Fig. 5C).  
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Figure 5 Schematic representation of osteogenic differentiation of hMSC. (A) 
Shows normoxic osteogenic differentiation. (B) Shows hypoxic osteogenic 
differentiation. (C) Shows hypoxic preconditioned osteogenic differentiation. Initially 
3000 cells/cm2 were seeded out in 6 wells and cultured for 3 days under normoxia 
and hypoxia. The cells were then induced into the osteogenic lineage for 21 days 
either by maintaining them at 21% O2 (A) or 2% O2 (C) or were transferred from 
normoxia to hypoxia (B). Abbreviations: NI: normoxia induced; NC: normoxia control; 
HI: hypoxia induced; HC: hypoxia control; PI: preconditioned induced; PC: 
preconditioned control.  
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2.9 Induction of adipogenic differentiation 
For adipogenic differentiation, SCP-1 were seeded in 6 well plates (NUNC, 
Wiesbaden, Germany) at a density of 5000 cells/cm2. They were cultured under 
normoxia or hypoxia until they were 90% confluent, which was reached after 3-4 
days in culture. Following 90% confluency, 3 out of the 6 wells in each plate were 
induced to differentiate by adding the adipogenic differentiation medium. The 
differentiation medium consisted of DMEM high glucose medium (PAA Laboratories 
GmbH, Pasching, Austria) supplemented with 10% FBS, 40 IU/ml 
penicillin/streptomycin, 4mM L-Glutamine, 1 µM Dexamethasone, 0,2 mM 
Indomethacin, 0,01 mg/ml insulin and 1mM 3-isobutyl-1-methyl-xanthine. Following 5 
days of induction cells were maintained for 2 days using the maintenance medium 
which consisted of DMEM high glucose supplemented with 10% FBS, 40 IU/ml 
penicillin/streptomycin, 4mM L-glutamine and 0,01 mg/ml of insulin. Induction 
followed by maintenance was alternatively changed for a period of 16 days. As a 
negative control, the remaining 3 wells were cultured further with complete medium. 
Every 3 days a medium change was carried out. 
 
2.10 Oxygen Measurements 
 
2.10.1 Principle of oxygen measurement 
The principle behind the oxygen measurement relies on two different dyes. One is 
the oxygen indicator whose phosphorescence intensity Iind, is dependent on the 
oxygen concentration whereas the other dye acts as the reference whose 
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fluorescence intensity, Iref, is independent of the oxygen concentration. The ratio of 
the luminescence intensities of the 2 dyes gives rise to the reference signal IR which 
corresponds to the concentration of O2 (123).  
 
ref
ind
R
I
I
I   
 
2.10.2 2D oxygen measurement 
The oxygen was measured in 2D using a SensorDish Reader (SDR, Presens, 
Regensburg, Germany). In brief 100.000 SCP-1 were seeded in duplicates into a 
sterile polystyrene 24-well multidish with integrated optical-chemical sensor that 
measures dissolved oxygen (OxoDish; Fig. 6). The oxygen sensors were already 
calibrated using a two point calibration by the manufacturer. Thereafter the oxodish 
was placed on the SDR and placed in the incubator and the oxygen was measured 
every hour over a period of 7 days. For illustrative purposes the data obtained from 
24 hours was pooled together and a standard deviation was calculated. The detailed 
mechanism is described in Volkmer et al., 2008 (86).  
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Figure 6 Oxygen measurement device for 2D culture. (A) Shows a 24-well 
multidish with integrated optical-chemical sensor that measures dissolved oxygen. 
(B) Shows an oxodish placed on a sensor dish reader (SDR).  
 
2.10.3 3D oxygen measurement 
Oxygen measurements in the centre of three-dimensional (3D) cell culture constructs 
were performed as described previously (Fig. 7C; 86). In brief, a needle type oxygen 
micro sensor (PreSens, Regensburg, Germany) was introduced into the geometric 
centre of a static 3D culture seeded with either 1 million P8-hMSC or with 1 million 
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SCP-1 cells (Fig. 7B). These oxygen micro sensors have a very thin and fragile tip 
with a diameter of 50 µm. The microsensor is housed in a commercially available 
hollow needle of diameter 0.4 mm (Fig 7A), in order to prevent any mechanical 
damages to the sensor while introducing it into the scaffold. Oxygen sensors were 
calibrated using a 2 point calibration with 100% CO2 equalling 0% O2 and 
surrounding air equalling 21% O2. For comparability with our previous studies, 
oxygen measurements were carried out over a period of 7 days (86). To avoid 
disturbance of O2 measurements, in these experiments medium was changed only 
every 4 days.  
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Figure 7 Static oxygen measurement in DBM scaffolds. (A) Shows a needle type 
oxygen microsensor (B) Shows a microsensor tip placed in the geometric centre of a 
scaffold. (C) Shows an experimental setup of oxygen measurement within a scaffold. 
 
2.11 Live-dead-assay 
To assess survival of cells on scaffolds, fluorescence microscopy based on 
incubation of cells with fluoresceindiacetate (FDA) and propidium iodide (PI; 
Fluka/Sigma, Munich, Germany) was performed as described previously (86). In 
brief, a stock solution of FDA was prepared by freshly dissolving 10 mg of FDA in 2 
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ml of pure acetone and by diluting this mix 1:500 with phosphate buffered saline 
(PBS). To obtain the final FDA / PI staining solution, the two components were mixed 
at a ratio of 1:1. Prior to evaluation by fluorescence microscopy, scaffolds were cut in 
halves. For staining, medium was removed and samples were washed with 0.5 ml 
PBS. Each sample was incubated for 1 minute with 500 µl FDA/PI staining solution. 
After discarding the dye, the wells were again washed with 0.5 ml PBS. 
Subsequently, samples were analysed by fluorescence microscopy using an Axiovert 
100 microscope equipped with a 75 W mercury lamp (Zeiss, Munich, Germany). To 
detect red and green fluorescence of dead and alive cells, respectively, the Zeiss 
filter sets #10 and #15 were used. Pictures were taken with a Zeiss black and white 
digital camera (AxioCam MRm) and processed with the Zeiss Axiovision software 
(AxioVs40 V 4.5.0.0). 
 
2.12 Hypoxia detection assay 
hMSC (P8) were seeded at a density of 1000 cells/cm2 on glass slides and incubated 
for 48 hours under either normoxia or hypoxia. Afterwards cells were treated with 200  
µM of pimonidazole hydrochloride dissolved in medium and incubated for another 2 
hours at the respective oxygen condition. Thereafter, the cells were washed with 
PBS, fixed in 4% paraformaldehyde and the immuno-staining was performed as 
indicated by the manufacturer‟s protocol (HypoxyprobeTM-1 Plus Kit, Millipore, 
Schwalbach, Germany). For immunostaining a primary fluorescein isothiocyanate 
(FITC)-conjugated mouse monoclonal antibody which was directed against 
pimonidazole protein adducts and a secondary mouse anti-FITC monoclonal 
antibody conjugated to horseradish peroxidase (HRP) were used. 
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2.13 Hif-1 western blot 
For direct detection of the Hif-1 Protein, a Hif-1 Western Blot was performed. 
Therefore, following exposure to hypoxia or normoxia (controls) for 72 hours, whole 
cell lysates were obtained. In brief, cells were washed in ice cold PBS and treated 
with 1x Laemmli Buffer and 0.2M DTT at a ratio of 1:4 and incubated for 2 minutes at 
room temperature. Thereafter, cells were harvested using a cell scraper and 
homogenised by sonification. Following this procedure, proteins were denatured at 
99˚C for 5 minutes. Prior to loading the cell lysates onto the gel, they were 
centrifuged at 10.000 x g for 10 minutes at 4˚C. 50 µl of the protein extract were then 
separated onto an 8% acrylamide SDS mini gel and transferred electrophoretically 
onto polyvinylidene fluoride membranes (PVDF, Roche Diagnostics, GmbH, 
Mannheim, Germany) using a Bio-Rad transferring unit (BioRad, München, 
Germany). The membranes were then blocked with 5% skimmed milk in Tris-buffered 
saline with 0.05% Tween-20 (TBST) for 2 hours at room temperature. Subsequently, 
membranes were incubated overnight at 4°C with the primary antibody anti-Hif-1 
(catalogue no. AB1536, R&D Systems, Wiesbaden, Germany) mixed in TBST in a 
1:1000 dilution. After that, the membranes were washed thoroughly with TBST and 
incubated with a horseradish peroxidase-conjugated (HRP-conjugated) secondary 
antibody for 1.5 hours at room temperature. The membrane was finally washed with 
TBST. The protein bands were visualized by treating the secondary antibody with the 
HRP substrate (Immobilon Western, Millipore, Schwalbach, Germany). This 
treatment resulted in a chemiluminescent signal, which was detected using X-ray 
film. To confirm loading of the protein, the membranes were stripped and probed for 
β-actin (catalogue no. sc-47778, Santa Cruz biotechnology, Heidelberg, Germany) 
mixed at a 1:4000 dilution in TBST. 
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2.14 WST-1 assay 
A WST-assay was performed in order to monitor the cell‟s metabolic activity during a 
prolonged exposure to hypoxia. For each time point (1, 3, 5, 7, 10, 13, 16, 18 and 21 
days) hMSC (P8) were seeded in duplicates in 6 well plates at a density of 500 
cells/cm2 and incubated under either normoxia or hypoxia. Thereafter, the cells were 
treated with the WST-I reagent (Roche Diagnostics, Mannheim, Germany) mixed 
with medium at a ratio of 1:10 and incubated for 4 hrs under normoxia. Subsequently, 
100 µl of the medium from each well were transferred into a 96 well plate and the 
optical density was measured at 450 nm using an ELISA reader.  
 
2.15 Growth kinetics 
For each time point (1, 3, 5, 7, 10, 13, 16, 18 and 21 days), hMSC (P8) were seeded 
in duplicates in 6 well plates at a density of 500 cells/cm2. Upon evaluation, cells 
were trypsinised, resuspended and counted using a standard haemocytometer.  
 
2.16 5-bromo-2‟deoxyuridine (BrdU) assay 
The BrdU assay represents a calorimetric immunoassay for the quantification of DNA 
synthesis, based on the measurement of BrdU incorporation during DNA synthesis. 
The assay was performed as according to the manufacturer‟s protocol. In brief cells 
were cultured in 24 well plates either in normoxia or hypoxia for a certain period of 
time. Twenty four hours prior to fixation, BrdU is supplemented into the culture 
medium for both normoxia and hypoxia samples. BrdU is a pyrimidine analogue and 
gets incorporated in place of thymidine into the DNA of proliferating cells. Following 
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24 hours incubation with BrdU cells are fixed and denatured and thereafter anti-BrdU 
peroxidase (POD) is given to the denatured cells that bind to the BrdU which have 
been incorporated into the newly synthesised, cellular DNA. The immune complexes 
are detected by the subsequent substrate reaction and quantitatively measured via a 
scanning multi well spectrophotometer at a wavelength of 450 nm and a reference 
wavelength of 690 nm. 
 
2.17 Alizarin red staining 
After a 20-day period of osteogenic differentiation in either normoxia or hypoxia cells 
were assessed for calcium depositions using the Alizarin red staining. The staining 
and the subsequent quantification were performed using an osteogenesis 
quantitation kit (Millipore, Schwalbach, Germany). In brief, cells were washed with 
PBS and then fixed at room temperature with 10% paraformaldehyde for 15 min. 
After fixation cells were washed with excess of distilled water and stained with 40 mM 
of Alizarin red solution for 20 minutes at room temperature. Thereafter cells were 
washed with distilled water to remove excess stain. Cells were lastly pictured under 
the above mentioned Carl Zeiss microscope and quantification was performed 
following the manufacturer‟s protocol. The extent of osteogenesis was quantified by 
extracting the stain and subsequent measurement of Alizarin red uptake against a 
standard curve of Alizarin red serial dilution. 
 
2.18 Oil red O staining 
After 16 days of adipogenic stimulation the cells were assessed for intracellular lipid 
droplets using Oil red O staining. Oil red O is a lysochrome diazo dye that stains 
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lipids and triglcerides on frozen sections. Cells were initially washed with PBS and 
then fixed with 4% formaldehyde for 2 minutes at -20˚C. Thereafter the excess of 
formalin was washed off with 50% ice cold ethanol. Cells were then stained with 0.2 
% Oil red O staining for 20 minutes at room temperature. Afterwards cells were 
washed with 50% ice cold ethanol followed by a washing step with distilled water and 
then pictured under the previously mentioned Carl Zeiss microscope. 
 
2.19 RT-PCR assays 
In order to investigate the temporal expression pattern of important osteogenic 
markers during the osteogenic differentiation reverse-transcription polymerase chain 
reaction (RT-PCR) was performed. To this end, cells derived from normoxic, hypoxic 
and preconditioned samples were plated in 6 well plates and the total RNA was 
isolated after different time periods (5, 16 and 21 days after induction of osteogenic 
differentiation). Total mRNA from cells was extracted using an RNeasy mini kit 
(Qiagen, Hilden, Germany). Following RNA isolation, hexamer-primed reverse 
transcription was performed using the cloned AMV first strand cDNA synthesis kit 
(Invitrogen, Karlsruhe, Germany). To detect the mRNA expression of OPN, ALP and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), RT-PCR was employed 
using the following primers:  
 
ALP forward- TACAACACCAATGCCCAGGT,  
ALP reverse- TTCCACCAGCAAGAAGAAGC (approximately 696 bps);  
 
OPN forward- CTGATGAACTGGTCACTGATTTTC,  
OPN reverse- CCGCTTATATAATCTGGACTGCTT (approximately 359 bps);  
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GAPDH forward- CAACTACATGGTTTACATGTTC,  
GAPDH reverse- GCCAGTGGACTCCACGAC (approximately 181 bps); 
 
To address the stemness profile of hMSC/SCP-1 under normoxia or hypoxia, cells 
were seeded at a density of 3000 cells/cm2 into 6 well plates. Total RNA was 
extracted after 21 days in culture. mRNA isolation and cDNA synthesis was 
performed as above mentioned. Semi quantitative RT-PCR against embryonic stem 
cell markers octamer 4 (OCT4) and NANOG were performed using the following 
primers: 
 
OCT 4 forward- GGGTGGAGGAAGCTGACAAC 
OCT 4 reverse- GCATAGTCGCTGCTTGATCG (259 bps) 
 
NANOG forward- ACCTCAGCCTCCAGCAGATG 
NANOG reverse- TGCACCAGGTCTGAGTGTTC (327 bps)  
 
To see whether hTERT expression was upregulated under hypoxia we‟ve seeded 
SCP-1 in 6 well plates at a density of 3000 cells/cm2 and cultured them for 21 days 
under normoxia or hypoxia respectively. Total RNA was extracted after 21 days. 
mRNA isolation and cDNA synthesis was performed as above mentioned. Semi 
quantitative RT-PCR was performed using the following primer pair: 
 
hTERT forward- ATGTGACGGGCGCGTACGAC 
hTERT reverse- GGCTGGAGGTCTGTCAAG (413 bps)  
 
The PCR products were analysed on a 1.5% agarose gel and subsequently the 
bands for OPN and ALP were quantified using the freeware image J 
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(http://rsbweb.nih.gov/ij/download.html). These readings were normalized to the 
GAPDH expression level, and the results were reported as relative expression.  
 
2.20 hTERT staining 
In order to validate whether hTERT was expressed in hypoxia, we performed an 
immuno staining against hTERT protein. SCP-1 were seeded at a density of 1000 
cells/cm2 on glass slides and incubated for 48 hours in normoxia or hypoxia. 
Afterwards cells were washed with PBS and fixed in 100% methanol for 10 minutes 
at -20˚C. Thereafter immuno staining was performed as described by Böcker et al., 
2008 (85). In brief cells were washed in PBS and thereafter blocked with 3% BSA at 
room temperature for 2 hours. Subsequently primary antibody anti-hTERT rabbit 
polyclonal antibody (Merck; CalBiochem, Darmstadt, Germany) at a dilution of 1:10 
was applied and incubated over night at 4˚C. The glass slides were washed with PBS 
to remove the excess primary antibody and incubated with the secondary antibody 
(Alexa Fluor 488 donkey anti-rabbit IgG, Invitrogen, Karlsruhe, Germany) at a dilution 
of 1:500 at room temperature for 1 hour. Thereafter glass slides were washed with 
PBS and the nuclei were counter stained with DAPI (Invitrogen, Karlsruhe, Germany) 
for 5 minutes at room temperature.  
 
2.21 Clonogenic assay 
The CFU-F (Colony forming unit-fibroblast) protocol was adopted from Grayson et al. 
(102). In brief hMSC/SCP-1 were cultured for time periods of 5, 10, 16 and 21 days 
either in normoxic (21%) or hypoxic (2%) conditions. Afterwards they were 
trypsinised and plated into 10 cm petri dishes at a density of 14 cells/cm2, and 
incubated at normoxic conditions for 16 (hMSC) or 12 (SCP-1) days. Following their 
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respective incubation period the cells were washed with PBS and stained with 0.05% 
crystal violet solution for 30 minutes at room temperature. Afterwards the excess of 
crystal violet was washed off carefully with tap water and colonies were counted with 
the naked eye. 
 
2.22 Transient knockdown of HIF-1 with siRNA during osteogenic differentiation of 
hMSC 
In order to determine whether the differentiation as seen in preconditioned hypoxia 
samples were due to HIF-1we transiently downregulated HIF-1using silencing 
RNA (siRNA). HIF-1was selectively downregulated during the expansion culture of 
preconditioned samples (Fig. 8). Subsequently cells were osteogenically stimulated 
for 20 days or cultured with complete medium. On day 21 the success of 
differentiation was determined through Alizarin Red staining.  
 
 
Figure 8 Overview representation of osteogenic differentiation using siRNA 
against HIF-1. The role of HIF-1 on the osteogenic differentiation of hMSC was 
determined by transiently knocking down HIF-1  using silencing RNA during the 
expansion culture of preconditioned samples. 
 
HIF-1siRNA (h):sc-35561 was purchased from Santa Cruz biotechnology (Santa 
Cruz, California, USA), and the hMSC were transfected using lipofectamine 2000 
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from invitrogen using the latter‟s manufacturer‟s protocol. In brief 3000 cells/cm2 were 
plated out in 6 wells and incubated overnight at the respective oxygen conditions. 
The cells were transiently transfected as follows: 100 pmol of siRNA was dissolved in 
250 µl of Opti-MEM (Invitrogen, Karlsruhe, Germany) giving rise to solution A. 5µl of 
lipofectamine was dissolved in 250 µl of Opti-MEM giving rise to solution B. Solution 
B was incubated for 5 minutes at room temperature. Solution A and B were mixed 
together and left to stand for 20 minutes at room temperature. The oligomer-
lipofectamine 2000 complex was then added to the 6 well and incucbated at the 
respective oxygen concentration. After 5 hours of incubation medium was replaced 
with normal culture expansion medium. The cells were kept for 2 more days in 
culture before start of osteogenic induction. To determine the transfection efficiency, 
RNA was isolated from control samples and transfected cells, prior to differentiation. 
cDNA was synthesized and semi quantitative RT-PCR against HIF-1 was 
performed in order to detect the mRNA expression level of HIF-1 gene. Osteogenic 
differentiation (normoxia and hypoxia preconditioned) was carried out as previously 
described and the success of differentiation was evaluated through Alizarin red 
staining (Fig. 9).  
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Figure 9 Schematic representation of siRNA transfection experiment. Initially 
3000 cells/cm2 were seeded out in 6 wells and cultured for 24 hours under normoxia 
or hypoxia. Thereafter cells were transfected with siRNA against HIF-1. Fourty eight 
hours later the transfection efficiency was determined in the preconditioned samples. 
Cells were osteogenically induced for 20 days and on day 21 the success of 
differentiation was determined through Alizarin red staining. 
 
2.23 Stabilisation of Hif-1 with DFO during osteogenic differentiation of hMSC 
The hypoxia mimetic agent desferrioxamine (DFO) was used in order to test whether 
hypoxic samples were able to differentiate into the osteogenic lineage, if Hif-1 
protein would be stabilised during the expansion culture period in normoxia (Fig. 10). 
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Figure 10 Overview representation of osteogenic differentiation using DFO. The 
role of Hif-1 on the osteogenic differentiation of hMSC was determined by applying 
DFO to cells during the expansion culture of hypoxic samples. 
 
50 and 100 µM solutions of DFO dissolved in alpha MEM supplemented with 10% 
FBS and 1% PenStrep were prepared. Cells were seeded out in the normal fashion 
for osteogenic differentiation. Twenty four hours after plating cells were expanded in 
either 50 µM or 100 µM of DFO medium for an additional 2 days before they were 
stimulated to differentiate into the osteogenic lineage. Following 3 days of expansion 
culture some cells were used to obtain proteins. Proteins were isolated from hMSC in 
normoxia that were treated with 50 µM, 100 µM and 0 µM of DFO. Proteins were also 
isolated from cells that were cultured for 3 days under hypoxia. Western blot analysis 
against Hif-1 was performed using the protein samples. After the expansion culture 
cells were induced into the osteogenic lineage. For induction normal osteogenic 
differentiation medium without DFO was used. Cells which were used as control were 
cultured using complete medium without DFO supplements. Cells were induced for 
20 days and then hMSC were stained with Alizarin red staining (Fig. 11). 
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Figure 11 Schematic representation of DFO experiment. Initially 3000 cells/cm2 
were seeded out in 6 wells and cultured for 24 hours under normoxia or hypoxia. 
Thereafter the medium was supplemented with either 50 µM or 100 µM DFO and 
cultured for an additional 2 days under the same oxygen concentration. Proteins 
were extracted from cells that were cultured with and without DFO treatments in 21% 
O2 and in 2% O2. The osteogenic differentiation was pursued for 20 days and the 
success of differentiation was determined through Alizarin red staining on day 21. 
 
2.24 Statistical analysis 
Data are expressed as means +/- standard deviations. Statistic analysis was 
performed using the unpaired Student‟s T-test. The results were taken to be 
significant at a probability level of P < 0.05. For all experiments, a minimum of 2 
independent experimental runs were performed. 
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3 Results 
3.1 3D cultures of hMSC are exposed to low oxygen in vitro 
To assess whether hMSC in static 3D culture are exposed to hypoxia similar to 
murine fibroblasts (86) we measured the central oxygen concentration in scaffolds 
seeded with either hMSC or with hTERT-immortalized hMSC (SCP-1; 85) over a 
period of 7 days. The oxygen concentration in the central region of hMSC-seeded 
scaffolds dropped from 21% O2 at day 1 to around 2% of oxygen at day 4 (Fig. 12A; 
solid line). After the medium change on day 4, the oxygen level rose to approximately 
5.7% where it evened out. The well-growing SCP-1 cells in turn consumed the 
oxygen faster resulting in a decline to 0% at day 3 (Fig. 12A; dashed line). Upon the 
addition of fresh medium, the oxygen levels rose shortly to about 2% before they 
again dropped to 0%. A vitality assay after 7 days in static 3D culture revealed that 
the regular hMSC were literally all alive (green) and evenly distributed over the whole 
scaffold (Fig. 12B). In sharp contrast, hTERT-immortalized hMSC only survived in the 
periphery of the scaffold whereas in central regions of the scaffold only dead (red) 
cells were found (Fig. 12C). 
 
Results   52 
 
Results   53 
Figure 12 Oxygen concentration in static 3D culture of hMSC and hTERT-
immortalized hMSC in correlation to cell survival after 7 days in static culture. 
Oxygen concentration measured in the centre of DBM scaffolds seeded with 1 million 
hMSC falls to ~2% after 4 days and levels out at ~5.8% upon the addition of fresh 
medium (A; solid line). Oxygen concentration in the centre of scaffolds seeded with 1 
million hTERT-immortalized hMSC (SCP-1) falls to 0% after 3 days (A; dashed line), 
the addition of fresh medium after day 4 has only marginal effects. Live-dead-stain of 
hMSC-seeded scaffold after a 7-day-culture period reveals that virtually all cells are 
viable (green; B). The live-dead-assay of the hTERT-hMSC seeded scaffold reveals 
dead cells (red) in central and bottom areas of the scaffold and vital cells on the top 
and margins (C). Overview pictures were taken at 1.25 x magnification, inserts are 
representative pictures from the centre of the scaffold and were taken at 10 x 
magnification.  
 
3.2 Detection and confirmation of cellular hypoxia 
To demonstrate that the cells were exposed to hypoxic conditions in our hypoxia 
incubator, cells were incubated with pimonidazole, a chemical that forms adducts 
with cellular proteins solely under hypoxic conditions. Immunofluorescent staining 
was apparent only in cells exposed to hypoxia (2% O2) and not seen in those grown 
under normoxic conditions (Fig. 13A vs. 13B). To confirm that cells metabolically 
responded to lowered oxygen conditions, we assessed whether cells exposed to 2% 
oxygen activated the hypoxia inducible factor 1 alpha (Hif-1), a central regulator of 
the cellular response to hypoxia ubiquitously expressed in mammalian cells. As 
illustrated in Figure 7C, Hif-1 protein was detected in the hypoxic samples but not 
within the normoxic control samples (Fig. 13C). 
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Figure 13 Confirmation of cellular hypoxia. Cells were cultured on glass slides for 
48 hrs in (A) 2% or (B) 21% Oxygen, thereafter treated with pimonidazole for 2 hrs 
and immuno-stained. Black coloured cells indicate the presence of hypoxia-sensible 
pimonidazole adducts. Western blot analysis of Hif-1 reveals degradation of the 
protein in normoxic sample (N) and stable Hif-1 protein in the hypoxic (H) sample 
(C). 
 
3.3 Hypoxia promotes proliferation of hMSC 
We next asked whether hypoxia had an influence on cell proliferation and cell 
survival when compared to hMSC grown under normoxia. Therefore, hypoxic and 
normoxic cell samples were incubated with the WST reagent, a tetrazolium salt that 
is cleaved by the mitochondrial dehydrogenase of metabolically active cells into 
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formazan. Spectrophotometric quantification of formazan revealed that prolonged 
exposure to hypoxic conditions did not negatively affect cell survival and proliferation 
(Fig. 14A). To the contrary, after a lag phase of 5 days, during which hypoxia-
exposed cells produced less formazan, they began to metabolize more WST reagent 
than their normoxic counterparts until formazan production evened out at day 21 (Fig. 
14A). These differences were statistically significant at days 5, 13 and 18.  
 
To verify the WST results, cell numbers were determined over time in hypoxic 
samples compared to samples cultured under normoxia. Cells grew equally well 
under both conditions with a slight tendency towards a better growth under hypoxia 
(Fig. 14B). This difference, however, was statistically significant only at day 8. 
 
 
Figure 14 Cell viability and growth kinetic profile of hMSC grown under 
normoxia (21% O2) and hypoxia (2% O2). Cell viability was assessed by measuring 
the metabolic activity of normoxic cells (Norm; solid line) and hypoxic cells (Hyp; 
dashed line) using the WST reagent (A). After a lag phase of ~5 days, cells grew 
better under hypoxic conditions. These differences were statistically significant at 
days 5, 13 and 18. Data were obtained from 2 independent experiments done in 
duplicates and are presented as mean +/- standard deviation. The growth kinetic 
profile of hMSC grown under normoxia (21% O2) and hypoxia (2% O2) showed a 
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similar trend towards a better proliferation under hypoxia with statistical significance 
on day 8 (B). Data were obtained from 3 independent experiments done in duplicates 
and are presented as mean +/- standard deviation. Asterisks indicate the statistically 
significant difference between normoxia and hypoxia (* P < 0.05). 
 
3.4 Hypoxia increases DNA synthesis in hMSC 
We next screened whether the BrdU incorporation differed in hMSC grown under 
hypoxia (2%) to those grown under normoxia (21%). BrdU incorporation accounts for 
cells that are in their S phase, as these cells actively synthesize their DNA. BrdU is 
an anolog to thymine and gets incorporated into the sythesizing DNA strands in place 
of thymine. hMSC were grown either under normoxia or hypoxia for various time 
intervals and just 24 hours prior the evaluation BrdU was supplemented into the 
culture medium. At all time points the BrdU incorporation was higher in cells exposed 
to hypoxia than cells exposed to normoxia (Fig. 15). These differences were 
statistically highly significant at day 3, 7, 10 and 21 and significant at day 4. 
 
 
Figure 15 Impact of oxygen on DNA synthesis of hMSC. The BrdU incorporation 
was measured in hMSC that were either cultured under normoxia (21%) or under 
hypoxia (2%) for 3, 4, 7, 10, 16 and 21 days respectively. At any given point of time 
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the BrdU incorporation was significantly higher in cells that were exposed to hypoxia. 
Asterisks indicate the statistically significant difference between normoxia and 
hypoxia (* P < 0.05; ** P <0.005). 
 
3.5 Hypoxia inhibits osteogenic differentiation of hMSC 
To assess whether constant exposure to hypoxia has an impact on the capacity of 
hMSC to differentiate along the osteogenic cascade, we osteogenically differentiated 
hMSC in the presence of 21% oxygen compared to a 2% oxygen atmosphere. It is 
important to note that in contrast to several other studies assessing the osteogenic 
potential of cells under hypoxia, we exerted constant exposure to 2% oxygen over 
the full period of differentiation. While normoxic samples differentiated well as 
confirmed by a strong Alizarin red staining, samples differentiated poorly under 
hypoxia (Fig. 16A), suggesting a decrease or delay in osteogenic differentiation 
under low oxygen conditions. 
 
As a control, we monitored osteogenic differentiation by measuring the temporal RNA 
expression patterns of the representative osteogenic markers ALP and OPN (Fig. 
16B). The RT-PCR results revealed that the expression level of OPN under normoxia 
constantly increases from day 5 to 16 over day 21. The expression of ALP was 
equally high across the three time points indicating robust upregulation of osteogenic 
markers under normoxic osteogenic differentiation (Fig. 16B). In contrast, at day 16 
and 21, the expression of the two markers was clearly reduced when cells were 
differentiated under hypoxia. On day 5, in turn, upregulation of ALP was almost equal 
under hypoxia, whereas OPN expression was even higher in the hypoxic setting as 
compared to normoxic samples. 
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Figure 16 Osteogenic differentiation under hypoxia. hMSC that have been 
osteogenically induced under normoxia display strong Alizarin red staining whereas 
cells induced under hypoxia did not stain with Alizarin red (A). ALP and OPN RT-
PCR analysis was performed on RNA extracted from hMSC, which were 
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osteogenically induced under 2% oxygen or under normoxia for 5, 16 and 21 days. 
The expression level of OPN and ALP in the induced samples is remarkably lower in 
the hypoxic (HI) sample compared to normoxia (NI) except for OPN on day 5, where 
it is upregulated in the hypoxic induced sample. Abbreviations: ALP, alkaline 
phosphatase; OPN, osteopontin; NC, normoxia control; NI, normoxia induced; HC, 
hypoxia control; HI, hypoxia induced. 
 
3.6 Hypoxia favours stemness over differentiation 
Ma et al. described that the physiological niche of hMSC is hypoxic (70). We 
therefore speculated that the delay in osteogenic differentiation of hMSC seen in 
hypoxia is due to the fact that under reduced oxygen tension hMSC retain their stem 
cell characteristics. To assess the role of oxygen tension on the maintenance of 
stemness of hMSC in culture, we performed a clonogenic assay. The CFU-F assay 
revealed that cells exposed to hypoxia generated more colonies compared to those 
hMSC that were exposed to normoxia (Fig. 17A). The difference was statistically 
significant on days 16 and 21 respectively (Fig. 17B). It was also noticed that the 
colony numbers were maintained by the cells that were exposed to hypoxia over the 
time periods of 5, 10, 16 and 21 days. In contrast the cells exposed to normoxia 
showed a decreasing number of colonies over time, with day 5 and day 21 having the 
highest and least number of colonies respectively. 
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Figure 17 Clonogenic assay of hMSC. Cells were exposed to normoxia or hypoxia 
for 5, 10, 16 or 21 days and thereafter trypsinised and seeded into new 10 cm petri-
dishes at a density of 14 cells/cm2. The cells were then allowed to incubate at 37˚C 
for 12 days prior to crystal violet staining. The staining revealed that at any given time 
point, hMSC that were exposed to hypoxia formed more colonies (A). Quantification 
of the CFU-F assay revealed that the difference in colony numbers was significant at 
day 16 and 21 respectively (B). Asterisks indicate the statistically significant 
difference between normoxia and hypoxia (* P < 0.05). 
 
To further validate these findings we screened for the expression of embryonic stem 
cell markers NANOG and OCT 4. The embryonic transcription factor OCT 4 is one of 
the earliest marker expressed during embryogenesis in mammals (69). NANOG is 
another important transcription factor that is believed to be involved in the self-
renewal of undifferentiated embryonic stem cells. The semi quantitative RT-PCR 
showed a subtle upregulation of OCT 4 and a robust upregulation of NANOG in the 
hypoxic samples when compared to normoxia (Fig. 18). 
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Figure 18 Semi quantitative RT-PCR of embryonic stem cell marker. Semi 
quantitative RT-PCR of NANOG and OCT 4 was performed on RNA extracts from 
hMSC, which were cultured under 2% oxygen (H) or under 21% oxygen (N) for 21 
days. There was a clear cut upregulation in the hypoxic samples for NANOG, and a 
subtle upregulation for OCT 4 compared to their normoxic counterparts. 
 
3.7 Hypoxic preconditioning restores hypoxia-induced delay in osteogenic 
differentiation 
Recently Rosova et al. showed that preconditioning hMSC under hypoxic conditions 
prior to transplantation would enhance their therapeutic potential (117). Another 
study revealed that pre-treating hMSC in a non-lethal hypoxic environment would 
prevent or delay the development of apoptosis when cells were subsequently 
exposed to lethal hypoxic conditions (118). Because osteogenic differentiation is a 
crucial quality of cells which are aimed at regenerating bone tissue, we wondered 
whether preconditioning hMSC in hypoxia would improve their potential to 
differentiate along the osteoblastic lineage under constant hypoxia. To evaluate this 
hypothesis we cultured cells under hypoxia (2% O2) for three days prior to osteogenic 
differentiation at 2% O2. This time frame was selected as the cells needed around 3 
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days to reach about 70-80% confluency, which was in turn a precondition to start 
osteogenic differentiation. We termed this setup “hypoxic preconditioning” in 
distinction to the protocol of hypoxic differentiation described above, where cells were 
first grown to 70-80% confluency in normoxia and thereafter osteogenically 
challenged under hypoxia (Tab. 2).  
 
Placing the cells into the hypoxia incubator for 3 days prior to adding the 
osteoinductive medium resulted in restoration of the differentiation capacity as 
substantiated by a positive Alizarin red staining (Fig. 19A). Quantification of the 
Alizarin red staining showed a decreased but sizeable extent of staining within the 
preconditioned samples compared to normoxic samples, whereas there was literally 
no detectable Alizarin red staining in samples from the hypoxic setup without 
preconditioning (Fig. 20A). The RT-PCR results disclosed that hypoxic 
preconditioning restored both OPN and ALP upregulation upon osteogenic induction 
at days 16 and 21 (Fig. 19B). Quantification of the PCR-bands normalized to GAPDH 
expression showed increased levels of OPN and ALP on day 16 within the 
preconditioned samples when compared to the hypoxic samples, however without 
statistical significance (Fig. 20B). 
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Figure 19 Hypoxic preconditioning restores hypoxia-induced inhibition of 
osteogenic differentiation of hMSC. Cells were cultured under hypoxia (2%) for 3 
days prior to osteogenic induction and thereafter maintained at 2% oxygen 
(preconditioned samples; PI). Cells were induced for 20 days and then stained with 
Alizarin red (A). Preconditioned samples did differentiate under hypoxic conditions 
indicating that hypoxic preconditioning restores hypoxia-induced inhibition of 
osteogenic differentiation. RT-PCR of preconditioned samples documents robust 
upregulation of osteogenic markers OPN and ALP.  Abbreviations: ALP, alkaline 
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phosphatase; OPN, osteopontin; PC, preconditioned control; PI, preconditioned 
induced.  
 
 
Figure 20 Quantification of Alizarin red staining and of RT-PCR results. Data 
from normoxic, preconditioned, and non-preconditioned samples substantiates that 
hypoxic preconditioning restores hypoxia-induced inhibition of osteogenic 
differentiation. Quantification of Alizarin red staining of normoxic (N), preconditioned 
(P), and hypoxic (H) samples showed a significantly enhanced mineralization of 
induced normoxic and induced preconditioned samples when compared to induced 
hypoxic samples (A). Quantification of RT-PCR bands normalized to GAPDH using 
the image J software revealed a trend towards a better differentiation after 
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preconditioning (PI), with differentiation being best under normoxic conditions (NI; B). 
Asterisks indicate the statistically significant difference (P < 0.05) between normoxic 
induced and hypoxic induced (*) as well as between normoxic induced and 
preconditioned induced (**) samples. Abbreviations: ALP, alkaline phosphatase; 
OPN, osteopontin; NI, normoxia induced; HI, hypoxia induced; PI, preconditioned 
induced. 
 
3.8 The effect of hypoxic preconditioning on osteogenic differentiation is not donor 
dependent 
In order to verify that the effect of hypoxic preconditioning of hMSC on osteogenic 
differentiation at low oxygen tension is not donor dependent we carried out the 
osteogenic differentiation experiment using the 3 different experimental setups, in 
either normoxic, hypoxic or hypoxic preconditioning with 2 more donors. The Alizarin 
red staining after 20 days of induction clearly showed strong staining in the normoxia, 
hardly any in hypoxic induced samples and reduced staining in the preconditioned 
induced samples (Fig. 21A and B).  
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Figure 21 Osteogenic differentiation of two additional donors under normoxia, 
hypoxia and under hypoxia after hypoxic preconditioning. P6 hMSC of two 
further donors, a 24-year old male (A) and a 32-year old male (B), that have been 
induced osteogenically under normoxia for 21 days display strong Alizarin red 
staining (left panels). Cells induced under 2% of oxygen (hypoxia) under otherwise 
identical circumstances do not stain with Alizarin red (middle panels). After a phase 
of hypoxic preconditioning, where cells were cultured under 2% hypoxia for 3 days 
prior to osteogenic induction, hMSC from both additional donors (A and B) 
differentiated towards the osteogenic lineage under hypoxic conditions (2% of 
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oxygen) as evidenced by re-established Alizarin red staining (right panels), indicating 
that hypoxic preconditioning restores hypoxia-induced inhibition of osteogenic 
differentiation. 
 
3.9 HIF-1 does not play a major role in osteogenic differentiation of hMSC 
Wang et al. reported that HIF-1 is important in the development of the skeleton 
system as it couples angiogenesis to osteogenesis (94). Another group has shown 
that the HIF-1 pathway accelerates bone regeneration (118). We therefore asked 
whether HIF-1 had a direct link to osteogenic differentiation. In order to determine 
whether HIF-1 plays a major role in the osteogenic differentiation of hMSC under 
low oxygen tension, we transiently knocked down HIF-1 using silencing RNA during 
the expansion culture of preconditioned samples (Fig. 8). The transfection efficiency 
of siRNA against HIF-1 as determined through semi quantitative RT-PCR revealed 
a good efficiency: The expression of HIF-1 from cells cultured for 3 days under 
hypoxia showed a strong band compared to those cells that were cultured under 
hypoxia and transfected with siRNA against HIF-1, which showed a very faint band 
(Fig. 22C). Transiently knocking down of HIF-1 had no apparent effect on the 
osteogenic differentiation ability of hMSC under hypoxia as evidently seen with 
Alizarin red staining (Fig. 22A). As a control hMSC under normoxia were transfected 
with siRNA against HIF-1. Preconditioned hMSC transiently transfected with siRNA 
against HIF-1 differentiated as well as cells without transfection as seen via the 
Alizarin red quantification (Fig. 22B). 
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Figure 22 The effect of transiently knocking down of HIF-1during expansion 
culture of hypoxic preconditioned sample on osteogenic differentiation. hMSC 
were seeded for osteogenic differentiation into 6 wells in normoxia and hypoxia 
respectively. Twenty four hours after plating they were transiently transfected with 
silencing RNA against HIF-1. After 3 days they were osteogenically induced. hMSC 
that were either transfected or not transfected in normoxia or hypoxia were stained 
with Alizarin red after 20 days of induction. (A) Alizarin red quantification showed no 
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significant differences between the transfected and not transfected samples in either 
oxygen conditions (B). After 3 days the transfection efficiency was determined 
through RT-PCR of HIF-1There was a strong band of HIF-1 in the preconditioned 
not transfected sample (lane 1; C) and a very weak band was seen in the transfected 
sample (lane 2; C). Abbreviations: Norm-N: Normoxia not transfected; Norm-siRNA: 
Normoxia with silencing RNA against HIF-1; PC-N: Preconditioned not transfected; 
PC-siRNA: Preconditioned with silencing RNA against HIF-1  
 
To further clarify the role of HIF-1 during osteogenic differentiation, desferrioxamine 
(DFO) was given to the cells during the expansion culture of hypoxic samples, 
stabilizing HIF-1 under normoxic conditions. This was done in order to see whether 
early activation of HIF-1 prior to osteogenic differentiation was the reason for the 
improved differentiation of hMSC under hypoxia as seen with hypoxic preconditioned 
samples compared to the hypoxic samples. As DFO, a well known hypoxia-mimetic 
agent, is known to induce apoptosis in a HIF-1 independent mechanism, we 
conducted the experiment with 2 low concentrations of DFO (124). The 
concentrations were chosen in such a way that the effect of DFO induced apoptosis 
was kept low but the DFO concentration was sufficient enough to stabilise Hif-
1protein under normoxia. Twenty four hours after plating the cells were incubated 
for 2 days with either 50 µM or 100 µM of DFO and thereafter induced into the 
osteogenic lineage without DFO treatments. Hypoxic differentiation did not result in 
any mineralisation as indicated through the Alizarin red staining for both the 50 and 
100 µM DFO treated cells (Fig. 23A and 23B). As a control normoxic and 
preconditioned samples were treated with 50 µM or 100 µM of DFO during their 
expansion culture, in order to see whether DFO itself had an effect on osteogenic 
differentiation. In either condition cells differentiated indicating that DFO itself did not 
Results   70 
have an impact on the osteogenic differentiation potential of hMSC. Even though the 
cells were only incubated for 2 days with either 50 µM or 100 µM of DFO during the 
expansion culture one observed that the cells did not tolerate the treatment with DFO 
well. This effect was dose dependent as with 100 µM of DFO lesser number of cells 
survived and differentiated into the osteogenic lineage compared to cells treated with 
50 µM of DFO, as evidently seen particularly in the normoxic samples (Fig. 23A and 
23B). On treatment with either 50 or 100 µM DFO the cells expressed stably the Hif-
1 protein even under normoxia as indicated through the western blot (Fig. 23C). 
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Figure 23 The effect of stabilising Hif-1 on osteogenic differentiation under 
hypoxia. hMSC were seeded for osteogenic differentiation into 6 wells for hypoxia, 
normoxia and preconditioned samples. After 24 hours the medium was 
supplemented with 50 µM DFO (A) or 100 µM DFO (B) and incubated for additional 2 
days. After 3 days proteins were isolated from hMSC in normoxia that were treated 
with 50 µM (lane 1), 100 µM (lane 2) and 0 µM (lane 3) of DFO (C). In addition to that 
protein was isolated from hMSC in hypoxia (lane 4). Western blot analysis against 
Hif-1 was performed with the protein samples. After 3 days cells were then 
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differentiated into the osteogenic lineage without DFO supplements. Following 20 
days of induction hMSC were stained with Alizarin red. hMSC exposed to 50 µM and 
100 µM DFO in normoxia and preconditioned samples stained with Alizarin red, 
whereas hypoxic sample did not, suggesting that HIF-1 does not play a crucial role 
in the osteogenic differentiation of hMSC under hypoxia. Note that DFO had a dose 
dependent effect on cells. 
 
3.10 Impact of low oxygen tension on SCP-1 
After having established that the osteogenic differentiation potential of hMSC is 
delayed under hypoxia, and that this in turn could be overcome through hypoxic 
preconditioning, we now aimed at transferring this knowledge to SCP-1, an 
immortalised hMSC cell line that was created in our lab. Böcker et al. have 
characterized this cell line and compared it to hMSC. They were able to show that 
the SCP-1, despite of their immortalization still possessed all the characteristics of a 
mesenchymal stem cell (85). Apart from being immortalised the other advantage of 
this cell line is that it is a fast growing cell line. This cell line represents an ideal 
model cell line to test various hypotheses as it is easy to handle, inexpensive and 
can be expanded to a desired cell number in a very short period of time compared to 
hMSC. We therefore initially characterised the cell line with respect to hTERT 
expression, growth kinetics, by clonogenic assay and regarding embryonic stem cell 
marker expression. 
 
Analysis of the growth kinetics showed that SCP-1 grew equally well under normoxia 
and hypoxia until they reached 100% confluency on day 14 (Fig. 24A). Once they 
reached 100% confluency, cells cultured under hypoxic condition tended to attain a 
plateau phase whereas cells cultured under normoxia continued proliferation. After 
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21 days in culture the SCP-1 that were cultured under normoxia reached a cell 
number of 2 million cells, whereas the cells grown under hypoxia merely a number of 
900 thousand cells. Low oxygen tension had no apparent effect on DNA synthesis at 
all time points when compared to their normoxic counterparts (Fig. 24B). 
 
 
Figure 24 Growth kinetic profile and impact of low oxygen on DNA synthesis of 
SCP-1. The growth curves of SCP-1 grown under normoxia (21%) and hypoxia (2%) 
show a similar trend until day 14 where they become 100% confluent. Following day 
14 cells under hypoxia reach plateau phase whereas cells under normoxia still 
proliferate at an exponential rate (A). The BrdU incorporation was measured in SCP-
1 that were either cultured under normoxia (21%) or under hypoxia (2%) for 5, 7, 10 
and 16 days respectively. The BrdU incorporation in either oxygen concentration was 
the same independent of time (B). 
 
Nishi et al. reported that hTERT expression in human placenta was upregulated 
under hypoxia (125). In order to verify whether hypoxia had an impact on hTERT 
expression we performed an immuno staining against hTERT. In addition we also 
screened for hTERT expression at the mRNA level via RT-PCR. The hTERT staining 
revealed an equally positive signal for both normoxic and hypoxic samples. The 
hTERT staining (green; Fig. 25B) was primarily focused in the nucleus as evidently 
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seen with the counter stain DAPI (blue; Fig. 25A) which stains the nucleus. To further 
emphasize that hTERT resides in the nucleus, the green and blue channels were 
overlapped, resulting in a 100% overlap, giving rise to a turquoise blue nucleus (Fig. 
25C).  
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Figure 25 hTERT immuno staining. Cells were cultured on glass slides for 48 hours  
either in normoxia or hypoxia respectively and thereafter immunostained against 
hTERT protein using an anti-hTERT rabbit polyclonal antibody. (A) shows cells with 
DAPI staining, (B) shows cells with hTERT staining, (C) shows (A) + (B) overlapped 
(D) is (C) under phase contrast. (E) shows cells with the omission of primary antibody 
and stained with DAPI. (F) shows (E) under phase contrast.  
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To assess the role of oxygen tension on the maintenance of stemness of SCP-1 in 
culture, we performed a clonogenic assay. In addition to this we also screened for 
embryonic stem cell markers at the mRNA level via RT-PCR. Clonogenic assay 
showed that cells exposed in normoxia generated more colonies than those cells that 
were exposed to hypoxia. The difference was statistically significant at day 16 (Fig. 
26).  
 
 
Figure 26 Clonogenic assay of SCP-1. Cells were exposed to normoxia or hypoxia 
for 5, 10, 16 or 21 days, and thereafter trypsinized and seeded into new 10 cm petri-
dishes at a density of 14 cells/cm2. The cells were then allowed to incubate at 37˚C 
for 12 days prior to crystal violet staining. The staining revealed that at any time 
period, SCP-1 that were exposed to normoxia formed more colonies (A). The 
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difference in colony number was significant at day 16 (B). Asterisks indicate the 
statistically significant difference between normoxia and hypoxia (* P < 0.05). 
 
The expression of NANOG, OCT 4 and hTERT was slightly upregulated in the 
hypoxic samples compared to normoxia (Fig. 27).  
 
 
Figure 27 Semi quantitative RT-PCR of embryonic stem cell markers and 
hTERT. RT-PCR against NANOG, OCT 4 and hTERT was performed on RNA 
extracts obtained from SCP-1 that were cultured either in normoxia (21%) or hypoxia 
(2%) for 21 days. The embryonic stem cell markers and hTERT were slightly 
upregulated under hypoxic condition. 
 
3.11 Oxygen measurements of SCP-1 in 3D versus 2D culture 
In order to assess whether hypoxic preconditioning had an effect on cell survival in 
SCP-1-seeded DBM scaffolds, we determined the oxygen concentration at the core 
of the scaffolds. The oxygen concentration at the core of the scaffolds dropped down 
to zero after 2-3 days of initial seeding independent of the hypoxic preconditioning. 
After medium change on the 4th day the oxygen concentration rose slightly but 
dropped down to zero again during day 6 and 7 for normoxia and preconditioned 
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cells respectively (Fig. 28A and 28B). Overall there were no major differences 
noticed in the central oxygen measurements within the preconditioned and non-
preconditioned scaffolds. 
 
 
Figure 28 Central oxygen measurements within static DBM scaffolds seeded 
with SCP-1 Oxygen concentrations were measured at the centre of scaffolds that 
were either seeded with 1 million normoxic SCP-1 (N; A) or preconditioned SCP-1 
(PC; B). The central oxygen concentration in the scaffolds dropped from 21% to 0% 
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after 2-3 days and showed a small rise in the oxygen concentration at day 5 after 
medium was changed on day 4. The oxygen then dropped down to zero again. 
 
We already found out that SCP-1 are exposed to 0% oxygen after day 3 of initial 
seeding in static 3D culture (Fig 6A). We concluded that due to the depletion of 
oxygen within the centre the cells would simply die off. Wang et al. have shown that 
preconditioning cells under low oxygen would make them more resistant to a 
subsequent exposure to lethal oxygen concentration (118). We wanted to see 
whether this statement holds good for 3D culture as well, and speculated that by 
culturing the cells under hypoxia before seeding them on the scaffold they would 
have an improved life expectancy under such adverse oxgen concentrations. We 
therefore seeded 1 million SCP-1 that were either cultured for 3 days under normoxia 
or hypoxia on DBM scaffolds and cultured them for 7 days under static condition, in 
an humidified incubator having 5% CO2 and 21% O2. 3 days were chosen for hypoxic 
preconditioning as we wanted it to be comparable to our previous finding that 
preculturing hMSC for 3 days under hypoxia would improve their osteogenic 
differentiation potential at low oxygen tension (126). 
 
Live-dead staining after 7 days showed no significant differences between scaffolds 
that were seeded with preconditioned or cells grown under normoxia. In both 
conditions cells preferentially inhabited the periphery of the scaffold. The larger 
magnification (insert) showed dead cells within the core of the scaffold (Fig. 30A). 
The area quantification of green area versus red area further assured that there was 
no statistical significance between cell survivals of normoxic to preconditioned cells 
(Fig. 30B).  
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Figure 29 Live-dead assay of SCP-1 cultured on DBM scaffolds. 1 million of 
SCP-1 cells that were either cultured in normoxia (N) or preconditioned in hypoxia 
(PC) for 3 days were seeded on DBM scaffolds and cultured for 7 days in a static 
culture under normoxia. Live-dead-assay after 7 days revealed that almost all vital 
cells (green) reside at the periphery of the scaffold. Higher magnification (insert) 
showed dead cells (red) at the centre of the scaffold (A). Anyalysis of the % of green 
area to % of red area of the scaffolds did not show a significant difference between 
the 2 groups (B). 
 
In order to assess whether the oxygen consumption seen in the 3D culture of 
preconditioned and normoxic cells would be similar to 2D culture, we cultured SCP-1 
either in hypoxia or normoxia for 3 days and thereafter seeded equal numbers of 
preconditioned or normoxic cells on 24 well oxodishes and measured the oxygen 
concentration within the medium over a period of 7 days in static culture in an 
humidified incubator having a 5 % CO2 and 21 % O2. The oxygen measurements 
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performed in the 2D setting showed a gradual drop in the oxygen concentration for 
preconditioned and normoxic cells. Cells that were cultured in normoxia prior to 
oxygen measurements (normoxic) showed a drop in their oxygen concentration from 
15.7 to 12.8% (Fig. 29B solid line), whereas the cells that were cultured prior the 
oxygen measurement in hypoxia (preconditioned) showed a drop in their oxygen 
concentration from 16.1 to 13.4% (Fig. 29B dashed line). Although the oxygen 
consumption in 2D culture seemed to be generally less in those cells that were 
preconditioned compared to their normoxic counterpart, there was no statistical 
significance observed (Fig. 29B). Both preconditioned and normoxic cells reached 
100% confluency after 7 days in culture as shown in figure 29A. 
 
 
Figure 30 Oxygen measurement of SCP-1 grown in 2D culture. One hundred 
thousand SCP-1 cells that were either precultured in normoxia or hypoxia for 3 days 
were seeded in oxodishes and cultured for a period of 7 days under static culture in 
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normoxia. After 7 days both normoxic and preconditioned samples became 100% 
confluent (A). The oxygen concentration within the medium was measured and 
dropped gradually from 15,7 to 12,8% and 16,1 to 13,4% for normoxic and 
preconditioned samples respectively (B). 
 
3.12 The effect of hypoxic preconditioning on the differentiation capability of SCP-1 
To see whether the knowledge of hypoxic preconditioning and its effect on the 
osteogenic differentiation of hMSC is also transferrable to SCP-1, we cultured SCP-1 
under hypoxia (2% O2) until the cells reached a confluency of 70-80% and then 
induced them into the osteogenic lineage at 2% O2. Hypoxic preconditioning did 
indeed lead to osteogenic differentiation as evidenced through Alizarin red staining 
(Fig. 31B). We further asked whether this approach of hypoxic preconditioning could 
also be used to differentiate SCP-1 cells into other lineages such as into adipocytes. 
We therefore cultivated SCP-1 under hypoxic condition prior to start of adipogenic 
induction under the same oxygen tension. The Oil red O staining revealed that SCP-
1 even with hypoxic preconditioning did differentiate into the adipogenic lineage. The 
amount of vacuole formation was fewer in the hypoxic preconditioned samples than 
compared to their normoxic counterparts (Fig. 31A).  
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Figure 31 The effect of hypoxic preconditioning on adipogenic and osteogenic 
differentiation of SCP-1. Cells were cultured in hypoxia (2%) or normoxia (21%) for 
3 days prior adipogenic (A) or osteogenic induction (B) at 2% oxygen 
(preconditioned) or at 21% oxygen (normoxia). In both setups the differentiation 
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towards adipogenic and osteogenic lineage worked. In the adipogenic differentiation 
the vacuole formation was somewhat weaker in the preconditioned sample compared 
to normoxia. In the osteogenic differentiation there was no difference observed with 
Alizarin red staining. 
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4 Discussion 
4.1 Hypoxia as a limiting factor in cell-based tissue engineering 
The introduction of multipotent, proliferative hMSC from adult origin into regenerative 
medicine has driven speculations that the repair of large tissue defects will soon be 
within our reach (23, 127-130). However, several hurdles remain to be taken before 
adult progenitor cells will finally restore organ functions in vivo, one of which is 
adequate oxygen supply of cells in 3D constructs (86, 131, 132). This is especially 
true in the early phase after transplantation of cells when oxygen supply has yet to be 
established by the ingrowth of blood vessels (86, 133, 134). As cells are exposed to 
a reduced oxygen environment in literally any kind of regenerative cell therapy, a 
better understanding of the impact of hypoxia on cellular processes such as 
proliferation and differentiation is now warranted.  
 
4.1.1 Cells used for tissue engineering applications are exposed to hypoxia 
We have previously shown that mouse fibroblasts are exposed to significant oxygen 
gradients in 3D culture in vitro, even if dynamic culture systems are used (86). In the 
present study, we demonstrated that considerable oxygen gradients exist in static 3D 
cultures of hMSC as well. Similar to mouse preosteoblasts, the hTERT-immortalized 
hMSC (SCP-1) grew fast and therefore consumed the oxygen more rapidly, which 
resulted in cell death in central regions of the scaffold. The oxygen concentration 
declined to 0% in central areas of the scaffold and was virtually unaffected by the 
addition of fresh medium. When normal hMSC were seeded on the scaffolds, the 
oxygen dropped to only 2% and then levelled out at about 5.7% after one medium 
change. These findings suggest that normal hMSC adapt to the low oxygen 
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atmosphere better than hTERT-immortalized hMSC. One explanation may be that 
hMSC simply grow slower and thus have more time to slow down proliferation when 
oxygen levels decrease. In line with our findings, a recent study revealed that rat 
MSC (rMSC) tolerate low oxygen atmospheres better than rat cardiomyocytes 
because they utilised oxygen dependent metabolism more effectively (135). This trait 
was consequently termed metabolic flexibility, and we believe that, while hMSC 
preserved their metabolic flexibility, the transduction of hMSC with hTERT may have 
decrease their appropriate adaptive response to low oxygen tensions. Nonetheless 
hMSC were exposed to oxygen concentrations as low as 2% further emphasizing the 
importance of studying the cell behaviour and cell performance under reduced 
oxygen atmospheres. 
 
It is of paramount importance to define the oxygen conditions and their effect on the 
cells properly prior to analyzing further details of cell metabolism under hypoxia. In 
our study, cells were exposed to 2% of oxygen (hypoxia) in a hypoxia incubator, 
which guaranteed a constant experimental oxygen condition. We confirmed that 
exposure of cells to hypoxia resulted in true intracellular hypoxia by a positive 
pimonidazole staining, a chemical that forms intracellular adducts under roughly 1.5-
2% of oxygen. We further substantiated that cells were exposed to hypoxia by the 
detection of Hif-1 protein, a ubiquitously expressed mediator of the cellular 
response to hypoxia in mammalian cells, which plays a vital role in the activation of 
anaerobic metabolism, angiogenesis, erythropoiesis and vasodilation. The Hif-1 
protein is degraded when exposed to oxygen through its oxygen-dependent 
degradation domain. Under hypoxic conditions the Hif-1 protein is translocated into 
the nucleus where it binds to Hif-1 to form a stable heterodimer (91-94). It is 
important to note that Hif-1 is detectable on the mRNA level under both normoxic 
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and hypoxic conditions and that only on the protein level they are distinguishable 
(94). In our study, the Hif-1 protein was abundantly seen in the western blot 
analysis within the hypoxic samples, whereas no signal was found in the normoxic 
samples, further supporting that cells were undeniably exposed to hypoxia. 
 
4.1.2 Hypoxia promotes cell proliferation 
When performing hypoxia experiments, it is vital to assess the proliferation behaviour 
of the cells under normoxic as well as under hypoxic conditions. We showed that a 
prolonged exposure to 2% oxygen over a period of 21 days was neither cytotoxic nor 
did it negatively affect cell proliferation. Contrariwise, cells tended to grow better 
under hypoxia, and this trend was even statistically significant on days 5, 13 and 18 
when looking at the WST assays, and on day 8 when looking at the cell counts. 
Similar results were obtained by Grayson et al. who observed that hMSC exposed to 
2% hypoxia proliferated more rapidly than the normoxic cells (103). The same group 
showed that this trend persisted over several passages, and that hMSC maintained 
their growth rates even after confluency was reached. In parallel, a group that 
focused on the optimization of hMSC expansion cultures in vitro also found improved 
cell growth under hypoxia and therefore called for expansion cultures to be 
performed at low oxygen concentrations (114). Consistent with these results, it was 
shown that constant hypoxia promotes the proliferation of human bone marrow 
stromal cells (136), of human neural progenitor cells (137), and of human embryonic 
stem cells (138), suggesting that hypoxia promotes stem cell proliferation. On the 
contrary, culturing hMSC under hypoxia brought about a decrease in the proliferation 
and colony forming capacity of hMSC in two studies wherein hypoxia was applied 
Discussion   88 
intermittently (106, 139), indicating that sudden falls of oxygen tension negatively 
affect cell proliferation.  
 
4.1.3 Hypoxia inhibits osteogenic differentiation 
Differentiation processes are an inevitable step from multipotent precursor cells to 
bone tissue. As the hMSC in 3D culture were exposed to as little as 2% oxygen we 
aimed at clarifying the effect of constant hypoxia of 2% oxygen on the process of 
osteogenic differentiation of hMSC. We found a decreased extent of osteogenic 
differentiation under hypoxic conditions. This is in agreement with many studies 
which found a negative effect of hypoxia on osteogenic differentiation of mouse (104, 
107, 136, 140), rat (110), and human (69, 106, 107) bone precursor cells. 
Interestingly, however, on day 5 we discovered OPN to be more abundantly 
expressed under hypoxia than under normoxia when analysed by RT-PCR. Similar 
observations were made previously in rat vascular smooth muscle cells (141), in 
mouse osteocytes (142), in human renal proximal tubular epithelial cells (143), and in 
hMSC exposed to anoxia (144). Osteopontin is an extracellular matrix protein that 
binds to cells via an RGD sequence that recognizes the v3 integrin (145). It has 
been attributed to regulate bone cell adhesion and matrix mineralization (145, 146). 
An additional intriguing feature of osteopontin is to promote macrophage infiltration 
and osteoclast recruitment (146). It is tempting to speculate that the physiological 
significance of increased osteopontin expression of cells exposed to hypoxia may be 
to attract macrophages and osteoclasts to the site of fractured bone thus setting off 
or maintaining the bone repair process. However, future studies will have to clarify 
this issue in more detail. 
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4.1.4 Hypoxia promotes stemness 
As hMSC showed a reduced capability to differentiate towards the osteogenic 
lineage under hypoxia, we aimed to find out whether this was partly due to a varying 
stemness potential in normoxia compared to hypoxia. It was already reported that 
bone marrow derived mesenchymal stem cells reside within stem cell niche under 
low oxygen tension that would keep them multipotent and prevent them to be 
committed towards a particular lineage (69). 
 
One of the easiest and relatively inexpensive approaches to compare the stemness 
potential between two groups of cells is by means of a clonogenic assay. The CFU-F 
number was higher for cells exposed to hypoxia compared to normoxia, indicating 
that hypoxic cells possess more stemness than normoxic cells. This finding is in 
accordance with previous studies done by Grayson et al. who determined that hMSC 
grown under hypoxia produced a higher CFU-F number compared to the CFU-F 
numbers produced by hMSC exposed to normoxia (103). Ezashi et al. showed that it 
would be better to culture human embryonic stem cells under hypoxic conditions 
rather than normoxia as it would prevent spontaneous differentiation as seen in 
normoxia (138). 
 
In support of these findings we could show that the embryonic stem cell markers 
OCT-4 and NANOG were upregulated under hypoxic conditions, further indicating 
that hypoxia favours stemness over differentiation. It is believed that the pluripotency 
of embryonic stem cells relies on a set of transcription factors that are centred around 
NANOG, OCT-4 and SOX-2 (55). OCT-4 also known as POU5F1 (POU class 
homeobox 1) is a homeodomain transcription factor which belongs to the class of 
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POU (Pit, Oct, Unc) class of transcription factors. It governs in part the pluripotency 
of ES, and it is often used as a marker for undifferentiated cells. NANOG is a 
transcription factor that is required for the self-renewal of undifferentiated embryonic 
stem cell markers (147). In mouse embryos NANOG expression is limited to the 
founder cells of the inner cell mass (ICM; 148). The ablation of NANOG expression 
within the founder cells results in failure to generate epiblasts (147). Its expression is 
high in ES and embryonic carcinoma cells (149), but gets downregulated upon 
differentiation (150). 
  
D‟ippolito et al. have shown that marrow isolated adult multilineage inducible (MIAMI) 
cells have an enhanced cell proliferation and an increase in DNA synthesis when 
grown under 3% O2. In addition to that they were able to show that low oxygen 
tension promotes stemness by elevated expression of embryogenic stem cell 
markers such as OCT4 and REX-1. Furthermore they could show enhanced 
expression of stage-specific embryogenic antigen 4 (SSEA-4) surface marker in cells 
that were cultured under hypoxic conditions through cytometric analysis. Above all 
they were able to show that low oxygen tension suppressed the osteogenic 
differentiation of human MIAMI cells (69). Taking the results from proliferation and 
differentiation under low oxygen tension together, it suggests that hypoxia is a key 
condition for promoting stem cell self-renewal rather than stem cell differentiation. 
 
4.2 Hypoxic preconditioning as a treatment for cells in tissue engineering applications 
The fact that human mesenchymal stem cells exposed to hypoxia stop to differentiate 
along the osteoblastic lineage does impose substantial difficulties when aiming at 
regenerating bone tissues in vivo. While maintaining adequate oxygen supply in vitro 
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seems to be a difficult but feasible task, it appears almost impossible to guarantee 
constant oxygen supply to cells after implantation in vivo. Within the last year, a 
series of studies provided evidence that hypoxic preconditioning of hMSC brought 
about enhanced cell survival, reduced apoptosis rates, an increased cell engraftment 
and cell motility as well as an enhanced therapeutic potential (117, 118, 139, 151). 
We therefore reasoned that hypoxic preconditioning of hMSC may also improve their 
potential to differentiate towards the osteoblastic lineage under constant low oxygen 
conditions. Our findings do support this theory as preconditioning hMSC in hypoxia 
restored their capacity to differentiate osteogenically under constant hypoxia (for a 
summary of the differentiation experiments see table 2). It was reported that rat cells 
cultured under low oxygen tension prior implantation lead to more bone formation 
compared to cultures grown at 21 % O2 (112). Oxygen is a potent regulator of 
multiple cell functions including cell metabolism and differentiation (94, 103, 137, 
152-154). We therefore assume that the process of osteogenic differentiation is 
disturbed by changes in oxygen tension, whereas constant conditions support the 
process of differentiation. This would explain why hMSC either differentiated under 
constant normoxia or if cells were grown in hypoxia for three days before they were 
differentiated under hypoxic conditions. Ezashi and co-workers reported that a 
reduced oxygen concentration maintained the pluripotent state of embryonic stem 
cells and reduced the amount of spontaneous differentiation seen under normoxia 
(138). Accordingly, several researchers have postulated that low oxygen 
concentrations more accurately resemble the stem cell niche and therefore preserve 
an increased stemness of hMSC (104, 112, 117, 155, 156). These discoveries may 
explain why the preconditioned samples did not differentiate as well as the normoxic 
samples. Taken these findings together, we assume that an important pretreatment 
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of hMSC prior to transplantation is to grow them under a low oxygen atmosphere in 
order to preserve their stemness and their differentiation capacity. 
 
Table 2 Overview of the experimental setup of osteogenic differentiation and 
their outcome. 
 
 
 
Collectively, our data suggest that prolonged exposure to oxygen levels of 2% 
enhances hMSC proliferation. We have provided evidence that transducing hMSC 
with hTERT may decrease their metabolic flexibility, a fact that has to be kept in mind 
if genetically modified stem cells are generated for regenerative medicine. We 
demonstrated that preconditioning under 2% of oxygen prior to osteogenic 
stimulation enhances the differentiation potential of hMSC if differentiation is carried 
out under constant low oxygen tensions. We believe that hypoxic preconditioning is a 
helpful tool for successful regenerative cell-based therapies.  
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4.3 HIF-1 has no direct effect on osteogenic differentiation 
As preculturing cells for 3 days under hypoxic conditions prior to osteogenic induction 
resulted in an improved osteogenic differentiation as compared to the normoxia-
hypoxia (hypoxic) samples, we speculated that the activation of HIF-1 during the 3 
days of preconditioning may play a role in the process of osteogenic differentiation of 
preconditioned samples. However, a transient knock-down of HIF-1 through the 
application of silencing RNA during the hypoxic preconditioning period resulted in no 
visible differences in the osteogenic differentiation behaviour, suggesting that HIF-1 
activation was not the reason why hypoxic preconditioned samples differentiated into 
the osteogenic lineage. In this experiment the transfection efficiency was high. 
However, even with very good transfection efficiency it is estimated that only about 
70% of HIF-1function is eliminated. In order to rule out that the remaining 30% 
would be enough to bring about an adequate osteogenic differentiation, we 
performed an experiment where we treated hypoxic cells with DFO during their 
expansion culture.  
 
Desferrioxamine (DFO) is an iron chelator that is commonly used in clinical 
applications to treat iron overload diseases. The DFO treatment prevented the 
degradation of Hif-1 in normoxia. Zhou et al. showed that hypoxia and its mimetic 
DFO upregulated Hif-1 compared to normoxia (157). Woo et al. showed that DFO 
enhanced Hif-1 accumulation via a cyclooxygenase-2 signalling pathway (158). 
Hydroxylation of HIF complexes via a family of oxygen sensitive prolyl hydroxylases 
(PHD 1,2,3) brings about E3 ligation and this in turn triggers the proteosomal 
degradation of the protein complex. Several compounds have been now identified 
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which can inhibit prolyl hydroxylase activity (159-161). DFO, a pharmacological 
compound inhibits PHD activity by taking away iron, which is required as a cofactor 
for its proper enzymatic function (119). In this particular experiment Hif-1of 
normoxia-hypoxia (hypoxic) samples was stabilized during the entire differentiation 
period, either during the expansion culture in normoxia with the help of DFO, and 
during the induction period under hypoxia. This setup therefore mimicked the hypoxic 
preconditioned sample with respect to Hif-1 stability, and hence one expected to 
see some extent of differentiation in the normoxia-hypoxia (hypoxic) sample, if one 
assumed that HIF-1 played a central role in bringing about osteogenic differentiation 
of hypoxic preconditioned samples. But despite of Hif-1stabilisation there was 
hardly any difference observed, when analyzed by Alizarin red staining. This further 
strengthens the notion that HIF-1 activation does not influence the ostegenic 
differentiation of hMSC under hypoxia. As a control we treated normoxic and 
preconditioned samples with DFO during the expansion culture to show that DFO 
itself would not interfere with osteogenic differentiation. In either case there was 
differentiation, indicating that even with DFO treatment cells were still able to 
differentiate. This is in line with previous publications which reported that DFO 
enhances alkaline phosphatase activity and stimulates osteocalcin secretion in MG-
63 bone cells (162, 163). Furthermore it was shown that moderate concentration of 
DFO was able to promote osteogenic differentiation in hMSC, and that -catenin 
signalling pathway might be responsible for DFO induced osteogenesis (164). 
 
The first experiment revealing the requirement of vascular supply for skeletogenesis 
was shown by Trueta and colleagues, who demonstrated that an interruption of blood 
supply to the growth plate of bone resulted in decreased bone mineralization and in 
the expansion of the hypertrophic zone in the growth plate (165, 166). Wang et al. 
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demonstrated through in vivo models that HIF-1 plays an important role in coupling 
angiogenesis to osteogenesis during skeletal development (94). They demonstrated 
that mice lacking VhL (Von hippel-lindau) protein in osteoblasts and therefore 
constitutively over expressed the HIF  complex, display an increased bone 
formation phenotype. This phenotype was also associated with an increased 
angiogenesis and vascular endothelial growth factor (VEGF) production. In further 
support of this, they were able to show that by inactivating HIF-1 in osteoblast 
resulted in a decreased bone volume and vascularity. In their study they were not 
able to demonstrate whether HIF-1 had a direct influence on osteogenisis, they 
have merely shown that HIF-1 drives the formation of bone via angiogenesis. It is 
now known that the HIF system plays an important role in the regulation of 
angiogenesis by hypoxia (167). In another paper it was noted that HIF-1  plays a 
key role in hypoxic preconditioning (168).  
 
Collectively previous studies have shown that HIF-1 is required for bone 
development in vivo, through the activation of angiogenesis. Taken together our data 
obtained from the experiments with silencing RNA where we transiently knocked-
down HIF-1 during the expansion culture of hypoxic preconditioned samples and 
the experiments with DFO, where we stabilised HIF-1 during the expansion culture 
of normoxia-hypoxia samples, show that HIF-1 does not play a central role in 
directing hMSC into the osteogenic lineage in vitro.  
 
4.4 SCP-1 as a model system 
Progenitor cells like MSC are readily used in the field of cell based tissue engineering 
and gene therapy because of their ease of isolation and their multilineage 
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differentiation ability. However during long term in vitro culture of hMSC they undergo 
alteration in their physiological properties, and the mechanism underlying this still 
remains elusive (169). But their senescence-associated growth arrest under normal 
in vitro culture conditions restricts their clinical use. A reduced activity to undergo cell 
division, increased actin stress fiber formation, an increase in cell size and increased 
-glactosidase activity in vitro are signs of senescence (73). Numerous research 
groups have successfully overcome the problem of senescence-associated growth 
arrest by immortalizing hMSC through the introduction of the hTERT transgene. 
 
SCP-1 being an immortalised hMSC cell line has the advantage to be cultured to a 
high cell number within a relatively short period of time. The growth kinetics revealed 
that SCP-1 proliferated at a much higher rate than hMSC under normoxia. This was 
in line with previous publications who have reported that immortalised adult stem 
cells showed an enhanced proliferation (170-172). We believe that immortalization of 
hMSC apart from prolonging their life span would also bring about the selection of a 
subset of the hetrogenous hMSC population that are faster growing. The fact that 
SCP-1 tend to reach plateau phase in hypoxia once they reach 100% confluency 
while under normoxia they keep growing might be explained in that hypoxia in 
general helps to retain stem cell characteristics. It has been previously shown that 
stem cells gown to a high confluency display higher rate of spontaneous 
differentiation (138). Therefore, the fact that SCP-1 grown in hypoxia reached a 
plateau phase earlier than the SCP-1 grown in normoxia might be a sign that hypoxia 
lowers the chance of spontaneous differentiation. 
 
Previous research has shown that hTERT is upregulated under low oxygen tension 
(125). In order to validate this we screened for hTERT at mRNA and protein level to 
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see any differences between SCP-1 that were either exposed to normoxia or 
hypoxia. Immuno staining against hTERT did reveal that in both oxygen conditions 
they expressed equally well the hTERT protein. On mRNA level though one could 
see a subtle upregulation in samples that were cultured in hypoxia in comparison to 
normoxia.  
 
From the RT-PCR results one could also deduce that embryonic stem cell markers, 
NANOG and OCT-4 were upregulated under hypoxic condition. This goes in line with 
the growth kinetic analysis that hypoxia preserves the stem cell characteristics of the 
cells. To our surprise the clonogenic assay showed a higher CFU number for cells 
that were exposed to normoxia which is in direct contradiction to the results obtained 
with the growth kinetic and RT-PCR of embryonic stem cell markers both indicating 
that cells exposed to hypoxia are more stem like than those cells exposed to 
normoxia. The gradual decrease in the CFU numbers over time could be explained 
due to the fact that as cells tend to stay longer in culture become more confluent and 
hence start to differentiate spontaneously towards a particular lineage, and hence 
they might loose their ability to form colonies. 
 
From our experiments with hMSC we realised that preconditioning hMSC in hypoxia 
before inducing them into the osteogenic lineage under hypoxia would result in an 
improved osteogenic differentiation. We tried now to transfer our knowledge with 
preconditioning onto SCP-1. We were able to show that upon preconditioning SCP-1, 
the cell line differentiated into the osteogenic and adipogenic lineages. This was in 
accordance with a previous publication showing that immortalised hMSC maintained 
their differentiation potential (173). Furthermore it was shown that hMSC 
overexpressing hTERT showed enhanced osteogenic differentiation ability (82) 
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whereas hMSC deficient in hTERT expression showed an impaired differentiation 
potential (174). The adipogenic differentiation results were in line with previous 
reports wherein it was shown that hypoxia suppresses adipogenic differentiation 
(107).  
 
In summary, SCP-1 seems to be a suitable candidate to be used as a model system 
for hMSC in vitro. It would be recommended to culture the cells under hypoxia as the 
low oxygen tension favours the stemness and prevents spontaneous differentiation. 
Hypoxic preconditioning prior to tissue engineering application would also be 
favourable as this would acclimatise the cells for their upcoming oxygen milieu at a 
site of ischemia where they would be used to trigger the regeneration of the injured 
tissue. 
 
4.5 Hypoxic preconditioning of SCP-1 does not improve cell survival in DBM 
scaffolds 
It has been shown that a large number of transplanted cells die within the initial days 
after transplantation. Several factors account for the cell death such as hypoxia, 
oxidative stress, inflammatory response and trophic factor deficiency. Research is 
ongoing to improve the life span of transplanted cells especially in the initial stages 
where viable vasculature and direct trophic support are absent. Various strategies 
have been followed up such as genetic manipulation of cells by overexpressing anti-
apoptotic and growth factor genes or by knocking down of pro-apoptotic genes in 
order to keep the cells alive during the critical initial stages after implantation where 
they are exposed to reduced oxygen tension (105, 175, 176). Even though these 
approaches seem to be quite promising, there are several issues to be addressed 
Discussion   99 
before clinical use. The primary concern with genetically modified cells is their safety 
issues associated with permanent gene alteration and their chance for inducing 
cancer in the patient. However recent investigations have shown a harmless new 
approach that would make the cells more resistant to hypoxic exposure without 
undergoing any genetic modifications, namely hypoxic preconditioning. In a recent 
study it was shown that preconditioning cells in low oxygen tension would make cells 
more resistant towards a subsequent exposure to low lethal oxygen tension (118). 
Wang et al. showed that hypoxic preconditioning of hMSC prior implantation would 
make them more resistant towards hypoxia/reoxygenation-induced apoptosis. They 
were able to show that this protective mechanism was due to the stabilization of 
mitochondrial membrane potential, upregulation of BCL-2 and VEGF, and promoting 
extracellular signal-regulated kinase (ERK) and AKT phosphorylation. Theus et al. 
showed that transplantation of hypoxic preconditioned embryonic stem cell derived 
neural progenitor cells into ischemic rat brain lead to increased early survival of 
transplanted cells and also accelerated behavioural recovery following stroke (177). 
Several researchers have shown that hypoxic preconditioning is neuroprotective 
against ischemic brain injury (178, 179). With this idea in mind we have grown 
preconditioned and non-preconditioned SCP-1 on DBM scaffolds and grew them 
over a period of 7 days under static culture. We had already shown that SCP-1 are 
subjected to lethal oxygen concentrations of 0% oxygen and would result in death of 
cells within the core of the scaffold. We now assumed that if we would precondition 
SCP-1 in hypoxia prior to seeding them onto the scaffold might result in a higher 
number of viable cells at the end of 7 days, due to the assumption that 
preconditioning makes them more resistant to subsequent low oxygen concentration.  
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We initially analyzed the central oxygen measurements within the scaffolds. Central 
oxygen measurements within the scaffolds over a period of 7 days in static culture 
did not show any significant differences. To our surprise, preconditioned scaffolds did 
not differ from non-preconditioned scaffolds concerning cell survival characteristics. 
We thus have to conclude that in our model system in vitro hypoxic preconditioning 
did not improve cell survival in scaffolds exhibiting hypoxia. At last we decided to see 
whether there would be any differences in the oxygen measurements in 2D, and 
henceforth we seeded equal number of preconditioned and normoxic cells in 
oxodishes and measured the oxygen consumption over a period of 7 days. The data 
showed that preconditioned cells consumed less oxygen compared to normoxic cells 
at all different time points of oxygen measurements. There were though no significant 
differences in the oxygen measurements between the two cell groups. It is thus likely 
that preconditioning does protect cells from hypoxia-induced cell death by down-
regulating oxygen dependent metabolism. However our model system was unable to 
pick up this preconditioning induced benefit.  
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4.6 Conclusion 
Taking the data together, we confirmed that constant exposure to low O2 does indeed 
reduce osteogenic differentiation of hMSC. We believe that hypoxia favours 
stemness over differentiation, but the differentiation under hypoxia can be restored 
via hypoxic preconditioning. Hypoxic preconditioning may help to restore the 
otherwise reduced osteogenic potential of hMSC, either within a hypoxic fracture 
environment or at the site of implantation of tissue engineered bone constructs. We 
therefore believe that hypoxic preconditioning is a helpful tool for successful 
regenerative cell-based therapies in bone tissue engineering. HIF-1 seems not to 
play a significant role in osteogenic differentiation of hMSC under hypoxia. SCP-1 
might be used as a model system for hMSC but constant monitoring of neoplastic 
transformation is mandatory.  
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Figure 32 Hypoxic preconditioning as an improved method for cell based 
tissue engineering. Autlogous stem cells are obtained via bone marrow aspiration. 
Mesenchymal stem cells are isolated via Ficoll gradient centrifugation and their 
plasticity nature on tissue culture flasks. They are expanded in vitro under hypoxia to 
the desired cell number and thereafter put into the site of fracture either via injection 
or seeded on biocompatible scaffolds and implanted at the site of fracture where they 
will aid in regenerating new healthy tissue. 
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4.7 Outlook 
As hMSC used in tissue engineering are subjected to low oxygen concentrations 
either in the 3D construct or at the site of defect, it is of critical importance to 
investigate how cells respond to hypoxia and how their regenerative and 
differentiation potential can be maintained despite exposure to hypoxia. We believe 
that hypoxia-preconditioned hMSC represent a more suitable candidate for tissue 
engineering applications than hMSC grown under normoxia because of their 
enhanced osteogenic differentiation potential under low oxygen tension and because 
of a putatively increased survival under hypoxia.  
 
In the future more studies are warranted in order to substantiate the potential of 
hypoxically preconditioned hMSC. Further experiments need to be conducted in 
order to answer questions like what hypoxic preconditioning does to hMSC and why 
it improves the osteogenic differentiation potential under hypoxia. One has also to 
figure out how long one needs to preculture hMSC and under which degree of 
hypoxia, in order to achieve optimal osteogenic differentiation potential and survival 
under reduced oxygen tension. The effect of hypoxic preconditioning as seen in vitro 
should also be looked at in vivo.  
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Summary 
Osteogenic differentiation of hMSC into osteoblasts is a prerequisite for subsequent 
bone formation. Numerous studies have explored osteogenic differentiation under 
standard tissue culture conditions, which usually employ 21% of oxygen. However, 
bone precursor cells such as hMSC reside in stem cell niches of low oxygen 
atmospheres. Furthermore, they are subjected to low oxygen concentrations when 
cultured on three dimensional scaffolds in vitro for bone tissue engineering purposes, 
and even more so after transplantation when vascularisation has yet to be 
established. Similarly, hMSC are exposed to low oxygen in the fracture 
microenvironment following bony injury. Recent studies revealed that hypoxic 
preconditioning improves cellular engraftment and survival in low oxygen 
atmospheres.  
 
In the present study we therefore investigated the osteogenic differentiation potential 
of hMSC under 2% O2 (hypoxia) in comparison to a standard tissue culture oxygen 
atmosphere of 21% (normoxia). The success of differentiation was validated through 
Alizarin red staining and RT-PCR analysis of osteoblast markers ALP and OPN. We 
assessed osteogenic differentiation of hMSC following hypoxic preconditioning to 
address whether this pretreatment is beneficial for subsequent differentiation under 
low oxygen tension. To validate our findings we carefully characterised the extent of 
hypoxia exerted on cells with respect to cell survival (WST assay) and proliferation 
(growth curve). Furthermore we also tried to elucidate the role of HIF-1 with respect 
to osteogenic differentiation under hypoxia via silencing RNA and DFO, a 
pharmacological agent. Finally we tested whether an immortalized hMSC-line (SCP-
1) would serve as a model system for hMSC. 
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We found that hMSC proliferate better if cultured under 2% of oxygen. We confirmed 
that osteogenic differentiation of hMSC is indeed inhibited under hypoxia. We 
showed for the first time that hypoxic preconditioning of hMSC prior to osteogenic 
induction restores osteogenic differentiation of hMSC under hypoxia. HIF-1 seemed 
not to play a significant role in osteogenic differentiation under hypoxia, as transiently 
knocking down of HIF-1 in preconditioned samples did not show any differences in 
their osteogenic differentiation. Moreover stabilising Hif-1 in hypoxic samples did 
not yield any osteogenic differentiation either substantiating the notion that HIF-1 
does not have a direct role in the osteogenic differentiation of hMSC under hypoxia. 
 
Together our data suggest that hypoxia favours stemness over differentiation by 
upregulating embryonic stem cell markers like OCT-4 and NANOG. Hypoxic 
preconditioning may help to restore the otherwise reduced osteogenic potential of 
hMSC, either within a hypoxic fracture environment or at the site of implantation of 
tissue engineered bone constructs. We therefore believe that hypoxic preconditioning 
is a helpful tool for successful regenerative cell-based therapies in bone tissue 
engineering. SCP-1 cells might be used as a model system for hMSC as they are 
easy to handle, can be cultured to a desired cell number within a very short period of 
time, are relatively inexpensive and above all do not go into senescence as seen with 
hMSC after approximately 20 passages. Apart from their distinct advantages SCP-1 
cells still maintain the specific CD markers characteristic for hMSC and are able to 
differentiate into adipogenic, osteogenic and chondrogenic lineages. However for in 
vivo experiments in animals a constant monitoring of neoplastic transformation is 
mandatory. 
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Zusammenfassung 
Eines der größten Probleme des zellbasierten „Tissue Engineering“ von Knochen ist 
das Vorkommen von Sauerstoffgradienten in dreidimensionalen Zell-Leitschienen-
Konstrukten sowohl in vitro als auch in vivo. Aber auch nach einer 
Knochenverletzung sind humane mesenchymale Stammzellen (hMSC), die die 
Knochenheilung unterstützen, einer reduzierten Sauerstoffkonzentration ausgesetzt. 
Es ist deshalb wichtig, die osteogene Differenzierung von hMSC unter erniedrigter 
Sauerstoffkonzentration zu untersuchen. In der vorliegenden Arbeit wurde zunächst 
untersucht, ob die osteogene Differenzierung von hMSC durch eine Kultivierung 
unter Hypoxia (2% Sauerstoff) beeinträchtigt wird. Da einige aktuelle Studien nun 
Hinweise dafür geliefert haben, dass eine hypoxische Präkonditionierung sowohl für 
das überleben von hMSC unter hypoxischen Bedingungen als auch für deren 
"Engraftment" nach Transplantation vorteilhaft ist, haben wir untersucht, ob eine 
hypoxische Präkonditionierung von hMSC zu eine Verbesserung der osteogenen 
Differenzierung unter konstant erniedrigter Sauerstoffkonzentration führt. 
 
In den vorliegenden Untersuchungen wurde die osteogene Differenzierung von 
hMSC unter 2% O2 (Hypoxie) im Vergleich zu 21% O2 (Normoxie) durch Alizarin-Rot-
Färbung sowie durch RT-PCR osteoblastärer Marker (ALP, OPN) untersucht. 
Anschließend wurden hMSC hypoxisch präkonditioniert um zu klären, ob diese 
Vorbehandlung die anschließende osteogene Differenzierung unter hypoxischen 
Bedingungen verbessert. Um die gewonnenen Ergebnisse zu validieren, wurden die 
Sauerstoff-Bedingungen sorgfältig charakterisiert, insbesondere wurde die 
Expression eines Hypoxie-Markers (Hif-1α) mittels Western-Blot-Analyse sowie das 
Proliferationsverhalten von hMSC unter Hypoxie vs. Normoxie mittels WST-Assay 
bestimmt. Außerdem wurde die Rolle von HIF-1 durch Modulation mittels silencing 
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RNA beziehungsweise eines pharmakologischen Wirkstoffes (DFO) auf die 
osteogene Differenzierung von hMSC unter Hypoxie untersucht. Im weiterem wurde 
getestet ob die immortalisierte Stammzelllinie SCP-1 als Modellsystem für hMSC 
geeignet ist. 
 
Unsere Untersuchungen haben ergeben, dass hMSC unter 2% Sauerstoff 
mindestens genauso gut prolifieren wie unter Normoxie. Ferner konnten wir 
bestätigen, dass die osteogene Differenzierung tatsächlich unterdrückt wird, wenn 
sie unter 2% Sauerstoff durchgeführt wird. Wir konnten zum ersten Mal zeigen, dass 
die osteogene Differenzierung unter 2% O2 wiederhergestellt werden kann, wenn die 
hMSC zuvor im hypoxischen Milieu vorkultiviert werden. HIF-1 scheint allerdings 
keine größere Rolle in der osteogene Differenzierung von hMSC unter Hypoxie zu 
spielen, da weder die herauf-Regulation noch die herunter-Regulation von HIF-1 
einen messbaren Effekt auf die osteogene Differenzierung hat. SCP-1 eignet sich als 
ein Modellsystem für hMSC, jedoch muss in vivo eine konstante Überwachung von 
tumorigenen Veränderungen gewährleistet sein. 
 
Das osteogene Differenzierungspotential von hMSC unter hypoxischen Bedingungen 
kann erhöht werden wenn sie zuvor hypoxisch präkultiviert werden. 
Dies ist von herausragender Bedeutung für regenerative zellbasierte Therapien, die 
Knochenregeneration nach Trauma oder bei Knochendefekten zum Ziel haben. 
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(P), and hypoxic (H) samples showed a significantly enhanced mineralization of 
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hypoxia and under hypoxia after hypoxic preconditioning. P6 hMSC of two further 
donors, a 24-year old male (A) and a 32-year old male (B), that have been induced 
osteogenically under normoxia for 21 days display strong Alizarin red staining (left 
panels). Cells induced under 2% of oxygen (hypoxia) under otherwise identical 
circumstances do not stain with Alizarin red (middle panels). After a phase of hypoxic 
preconditioning, where cells were cultured under 2% hypoxia for 3 days prior to 
osteogenic induction, hMSC from both additional donors (A and B) differentiated 
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Figure 22 The effect of transiently knocking down of HIF-1 on hypoxic 
preconditioned osteogenic differentiation. hMSC were seeded for osteogenic 
differentiation into 6 wells in normoxia and hypoxia respectively. Twenty four hours 
after plating they were transiently transfected with silencing RNA against HIF-1. 
List of figures   114 
After 3 days they were osteogenically induced. hMSC that were either transfected or 
not transfected in normoxia or hypoxia were stained with Alizarin red after 20 days of 
induction. (A) Alizarin red quantification showed no significant differences between 
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very weak band was seen in the not transfected sample (lane 2; C). Abbreviations: 
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